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SITUATION AND AIM 
 
Lactic acid bacteria (LAB) comprise a group of Gram-positive bacteria that are characterised 
by the production of lactic acid as the major end product of their carbohydrate fermentation. 
LAB are often used for the production and preservation of fermented foods and have as such 
obtained the ‘generally regarded as safe‘ (GRAS) status which makes them suitable for 
pharmaceutical applications. Some LAB are also commensals of the human gastro-intestinal 
or vaginal microflora.  
Health promoting effects are attributed to different strains of this group, referred as probiotic 
strains. Probiotics are defined as living microorganisms which confer a health benefit on the 
host when supplied in adequate amounts. In various disorders such as gastro-intestinal 
diseases, bacterial vaginosis and urinary tract infections probiotic strains have been shown to 
exert a beneficial effect (Naidu et al. 1999, Reid 2001, Reid 2005). In addition to their health 
promoting effect, LAB have been genetically modified to produce therapeutic proteins or 
peptides (Hanniffy et al. 2004) to obtain a therapeutic effect after administration.  
However, formulation of these microbial strains in a stable formulation containing a high dose 
of viable bacteria remains challenging due to the detrimental effects of dehydration and of 
gastric passage on the survival of the bacteria. This project focuses on the development of (a) 
an oral solid dosage form for the delivery of a genetically modified Lactococcus lactis strain 
and (b) a vaginal delivery system for delivery of different probiotic Lactobacillus strains. 
The aim of the first part of the thesis was to develop a dry formulation of a recombinant L. 
lactis Thy 12 strain. L. lactis Thy 12 was genetically modified in order to produce IL-10, an 
anti-inflammatory cytokine used in the treatment of Crohn’s disease (Steidler et al. 2003). The 
main challenges are (a) to design a formulation using a suitable production technique which 
1
preserves the viability of the bacteria since a high number of viable bacteria is required to 
obtain sufficient levels of therapeutic IL-10 at the target site and (b) to target the genetically 
modified organisms to the ileal part of the intestine which is the main inflammation site in 
Crohn’s disease patients. 
The aim of the second part of the thesis was to develop a suitable vaginal formulation for the 
efficient delivery of probiotic strains. The evaluated probiotic strains (Lactobacillus jensenii, 
Lactobacillus crispatus and Lactobacillus gasseri) were selected based on their characteristics 
(capacity to produce H2O2, inhibition of Gardnerella vaginalis, Atopobium vaginae and 
Escherichia coli) in relation to the treatment or prevention of bacterial vaginosis (Saerens 
2006). The main challenges are (a) to ensure the viability of the lactobacilli during processing 
(i.e. when dehydrated) and long term storage, (b) to obtain a long vaginal retention time of the 
dosage forms and (c) to have adequate colonisation of the probiotics in the vaginal cavity. To 
meet these challenges different dosage forms (layered multi-particulates, freeze-dried powder) 
were developed and the most suitable formulations/dosage forms were vaginally administered 
to healthy volunteers to evaluate the retention time, spreading of the formulation and 
colonisation potential of the selected strains.  
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1 
INTRODUCTION  
 
1.1. Introduction 
 
This research project focuses on the development of solid dosage forms for the delivery of 
micro-organisms. More specifically an oral formulation of a genetically modified 
Lactococcus lactis strain was developed in the first part, while the second part aims to 
develop a vaginal formulation of probiotic Lactobacillus strains.  
Genetically modified L. lactis organisms and their use in disease treatment are discussed in 
this introductory chapter. Furthermore, an overview is given about the pros and cons of the 
different vaginal formulations, and the use of Lactobacillus strains as probiotic therapy in 
bacterial vaginosis is described. The stabilisation of bacteria in dry formulations is reviewed, 
including drying techniques and stabilisation mechanisms. Since multi-particulate oral dosage 
forms are formulated in this study and fluid bed processing is used for drying and coating of 
the bacterial formulation, these aspects are also presented in this chapter.  
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1.2. Genetically modified Lactococcus lactis 
 
1.2.1. Crohn’s disease 
 
Crohn’s disease and colitis ulcerosa are the two most important forms of chronic intestinal 
inflammations in the Western world (Baumgart and Carding 2007). Crohn’s disease mostly 
affects the entire gastro-intestinal tract, whereas only the colon is inflamed in patients with 
colitis ulcerosa. The incidence of Crohn’s disease has increased in Europe and is mostly 
diagnosed in young adults. The disease is characterised by a transmural, discontinuous 
inflammation of the intestinal wall with ulcerations, strictures and fistulae. It predominates in 
the lower small intestine (ileum) and in the colon. Gut inflammation can lead to 
malabsorption of vitamins and the frequently occurring gastrointestinal bleedings can result in 
anaemia. Crohn’s disease is also associated with the occurrence of colon cancer. 
The etiology still remains partly unknown but it is common that there is an imbalance 
between pro- and anti-inflammatory modulators in the intestinal wall (Duchmann and Zeitz 
1999). Pro-inflammatory interleukins (IL-1, IL-6, IL-8), tumor necrosis factor alpha (TNF-α) 
and interferon gamma (IFN-γ) levels are elevated in the gastrointestinal tract of patients with 
Crohn’s disease, as a result of an abnormal T-cell response to commensal microflora in the 
gut. As in 2.2 – 16.2 % of the cases, patients have a relative member who is also affected, 
arguments arise that there is a genetic origin. As the incidence of Crohn’s disease in the 
Western world is much higher than in developing countries, environmental factors like food 
and living conditions also play a role in the pathogenesis of Crohn’s disease.  
Treatment consists on one hand of acute treatment of the active disease to bring the patient in 
remission and on the other hand of maintenance treatment to keep a patient in remission 
(Stites et al. 1994, Baumgart and Sandborn 2007). In patients with a mild form of the disease 
6
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aminosalicylates, sulfasalasin and mesalamin are used. In patients with an active 
inflammation corticosteroids are used, however due to adverse effects and resistance long 
term use of corticosteroids is not acceptable. Immunosuppressants are suggested as 
maintenance treatment. Often, surgery is necessary with bowel resection, however this does 
not induce complete healing as in 80 % of the patients relapses are reported within 1 year.  
Recently, biological treatment using cytokines, growth factors, monoclonal antibodies and 
probiotics has gained interest (Wilhelm et al. 2006; van Deventer 2000). Especially 
monoclonal antibodies like Infliximab® (which neutralises human tumour necrosis factor 
alpha) served well to keep patients in remission. Restoration of the intestinal mucosa was 
observed in patients under Infliximab® treatment.  
IL-10 is a cytokine with multiple anti-inflammatory and immunoregulatory activities, 
including T-cell/macrophage depression and inhibition of pro-inflammatory cytokines and 
interferon-γ synthesis (van Deventer et al. 1997). The importance of IL-10 in the regulation of 
mucosal inflammation has been demonstrated in several inflammatory bowel disease animal 
models. IL-10 deficient mice developed a severe transmural inflammation, which was 
prevented by administration of IL-10 (Kuhn et al. 1993). In a multi-centre, prospective, 
randomized, double-blind, placebo-controlled study, Crohn’s disease patients were treated for 
28 consecutive days with subcutaneous IL-10 in different doses. Endoscopic and clinical 
improvement (based on the Crohn’s Disease Activity Index score) was achieved by IL-10 
treatment. However, in high doses a pro-inflammatory effect was found after subcutaneous 
administration by the production of interferon-γ, which might be circumvented by local 
delivery to the intestinal mucosa (Tilg et al. 2002). 
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1.2.2. Use of recombinant L. lactis in human health 
 
L. lactis are Gram-positive non-pathogenic bacteria and are classified as “generally regarded 
as safe” (GRAS) following their long history of use for the production of fermented milk 
products. L. lactis can be genetically modified to produce antigenic proteins for oral 
vaccination or therapeutic proteins. Oral vaccination against infectious diseases has gained 
more interest, as via oral vaccination both mucosal and systemic immune responses can be 
elicited (Clark et al. 2001). Mucosal immunisation is important as the mucosal surfaces are 
the portals of entry for many pathogenic agents. Moreover, non-invasive vaccination implies 
more patient compliance. However, most of the vaccines under development are derived from 
attenuated pathogenic bacteria, with the associated risk of infection in infants, elderly or 
immunocompromised individuals. Therefore the use of non-pathogenic, non-invasive bacteria 
as vehicle for oral vaccination or even as vehicle for therapeutic proteins (e.g. IL-10 in 
Crohn’s disease treatment) is an attractive concept. Intravenous administration of IL-10 as 
pure protein results in adverse effects and local delivery by oral administration is difficult as 
IL-10 is highly acid sensitive. Moreover, the purification of pure IL-10 from its natural source 
is very compromising as it only occurs in very low amounts (Hanniffy et al. 2004). The 
effectiveness of L. lactis as delivery system for antigens or proteins was demonstrated in 
several studies (Hannify et al. 2004; Norton et al. 1995).  
Robinson et al. (1997) used L. lactis for mucosal delivery of a tetanus toxin fragment C 
(TTFC) via the oral route, resulting in a positive mucosal and systemic antibody response. 
Mice vaccination with L. lactis modified to produce TTFC in combination with IL-2 and IL-6 
showed a higher immune response than vaccination with L. lactis secreting only TTFC, 
indicating an adjuvant effect of the secreted IL-2 and IL-6 (Steidler et al. 1998). IL-10 
secreting L. lactis administered in a dose of 2 × 107 cfu resulted in a 50 % decrease in colitis 
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in mice treated with sodium dextran sulfate to induce colitis and prevented the onset of colitis 
in IL-10 deficient mice. The therapeutic effect was due to IL-10 synthesised de novo and not 
due to residual amounts in the inocula, as these remnants would denature under the acidic 
conditions of the stomach. The delivered bacteria should be alive, because UV-killed bacteria 
did not show a clinical effect. Active production of IL-10 was demonstrated in IL-10 deficient 
mice, as IL-10 was detected in the intestine. Two possible routes were proposed by which IL-
10 reaches its target: IL-10 secreted in the lumen can be absorbed by responsive cells or 
lactococci themselves may be taken up by M-cells (Steidler et al. 2000). 
As L. lactis itself has a very low innate immunogenicity, sequential oral inoculations can be 
taken without a significant increase in the antibacterial antibody response (Norton et al. 
1994). 
 
1.2.3. Biosafety aspects 
 
The use of genetically modified organisms requires some biosafety aspects to prevent 
spreading of the modified organisms in the environment or the dissemination of antibiotic 
selection markers or other genetic modifications to other organisms. To this end, the 
thymidylate synthase gene (Thy A), which is essential for the growth of L. lactis, was replaced 
by the expression cassette for human IL-10. The resulting strain was dependent on thymine or 
thymidine for growth and survival. As the hIL-10 gene was integrated in the chromosome, 
dissemination of the genetic modification by lateral gene transfer is minimized and no 
antibiotic resistance marker is required to guarantee stable inheritance of the transgene. And if 
the intact thyA gene was acquired by homologous recombination, the hIL-10 gene would be 
removed (Steidler et al. 2003). Moreover, as L. lactis lacks any evidence to multiply in vivo, 
no intestinal colonisation can occur. 
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1.3. Probiotic Lactobacillus strains for vaginal delivery 
 
1.3.1. Vaginal formulations 
 
1.3.1.1. Physiology of the vagina 
 
The vagina is a canal extending from the vulva to the cervix (Woolfson et al. 2000, Chien and 
Lee 2002). The fornix forms the connection between the vagina and the cervix, while the 
introitus is the part of the vagina close to the vulva, the external part of the female genital 
organs (Fig. 1). The vagina of an adult woman is 6-7 cm in length and is characterised by an 
exceptional elasticity. The vaginal wall consists of three layers: the epithelial layer, the 
muscular coat and the tunica adventia. The thickness of the epithelial layer changes during the 
menstrual cycle and is also age dependent. The vaginal epithelium is usually considered as a 
mucosal surface, although it has no goblet cells and no mucin release. The vaginal secretions 
are a mixture of different components, mainly transudates from the blood vessels and cervical 
secretions. The vaginal pH fluctuates around 4, due to lactic acid production by Lactobacillus 
strains present in the vaginal microflora. The surface of the vagina is composed of numerous 
folds increasing the surface area of the vaginal wall. The vagina has a rich blood supply and 
permeability to a wide range of compounds including peptides and proteins (Richardson and 
Illum 1992). The hepatic first-pass metabolism is avoided, because blood leaving the vagina 
enters the peripheral circulation via a rich venous plexus.  
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Figure 1 Lateral view of the female pelvis 
 
1.3.1.2. Vaginal formulations on the market 
 
For the development of an acceptable vaginal dosage form some essential requirements are 
proposed (Hussain and Ahsan 2005; Vermani and Garg 2000):     
  - easily applicable by the patient 
- good spreading leading to an even distribution of the drug 
- a sufficiently long retention time to maximise drug release 
- no irritation or feeling of dicomfort 
 
Different types of formulations are on the market, each with their advantages and 
disadvantages. The main group of commercially available vaginal delivery forms are semi-
solid dosage forms (creams and gels) used to deliver hormones, antibiotics or fungicides. Gels 
and creams have been identified as good delivery systems with ease in formulation and 
administration and a fast drug release. However, these vaginal forms are messy to apply, can 
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leak in the undergarments and give an uncomfortable feeling to the user (Broumas and Basara 
2000; Justin-Temu et al. 2004; Bentley et al. 2000). Moreover, semi-solid formulations may 
not allow accurate drug dosing due to non-uniform distribution in and leakage from the 
vaginal cavity. Multiple administrations are required as the retention time is limited (Hussain 
and Ahsan 2005). Similar problems were reported for pessaries although they are easier to 
apply and provide accurate drug dosing. Large differences in retention of semi-solid 
formulations between individuals were reported, varying from 1 to 81 % retained of the initial 
dose after 24 h (Chatterton et al. 2004). Brown et al. (1997) reported a loss varying from 9 to 
97 % two hours post-dosing in post-menopausal women. Barnhart et al. (2005) observed 
limited vaginal mucosal coverage 24 h after application of a microbicidal vaginal gel. 
Hydrogels offer prolonged residence due to their swelling and bioadhesive nature leading to 
controlled release of the drug (das Neves and Bahia 2006).  
Vaginal tablets are easy to apply by the user, but vaginal disintegration of conventional tablets 
can be slow and due to gravity the tablets are rapidly cleared from the vagina. This can be 
reduced using bioadhesive vaginal tablets, but some studies even reported the loss of 
bioadhesive tablets after vaginal application (Voorspoels et al. 2002). 
Vaginal rings are torus-shaped polymeric devices, most often silicone- or ethylene vinyl 
acetate-based (EVA), designed to release one or more drugs in a controlled fashion 
(Alexander et al. 2004). Compared to other vaginal delivery systems, they provide a more 
accurate and sustained drug dosing, but due to the specific production process not all drugs 
can be incorporated into vaginal rings.  
Most of the vaginal formulations are cleared too fast from the vaginal epithelium as a result of 
the self cleansing action of the vagina and/or because the vaginal formulation failed to attain a 
proper distribution over the vaginal mucosa. 
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1.3.2. Lactobacillus strains 
 
1.3.2.1. Bacterial vaginosis 
 
Bacterial vaginosis (BV) is the most common cause of vaginitis in women of childbearing age 
(Sobel 2000). A major symptom is an unpleasant smelling, grey-white, thin and homogeneous 
discharge. Usually there is no pruritus or inflammation and most patients are symptom free. 
However BV can lead to severe complications, as several studies demonstrated an increased 
risk of abortion in the first trimester and pre-term birth in women with bacterial vaginosis 
(Hillier et al. 1995). A significant association exists between the human immunodeficiency 
virus (HIV) and bacterial vaginosis, suggesting the hypothesis that control of BV can reduce 
HIV transmission (Schmid et al. 2000).  
Diagnosis in clinical practice is based on simple diagnostic criteria proposed by Amsel et al. 
(1983):  
- an adherent homogeneous grey-white vaginal discharge 
  - “fishy smelling” odour when potassium hydroxide is added to the discharge 
  - an elevated vaginal pH (> 4.5) 
- presence of clue cells, which are vaginal epithelial cells heavily coated with 
bacteria 
 
BV is characterised by a reduction in the prevalence and concentration of H2O2-producing 
lactobacilli and an increase in the prevalence and concentration of Gardnerella vaginalis, 
Atopobium vaginae, Mycoplasma hominis, anaerobic Peptostreptococcus species and 
anaerobic Gram-negative rods belonging to the genera Prevotella, Porphyromonas and 
Bacteroides (Fig. 2). The massive overgrowth with vaginal anaerobes is associated with the 
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production of carboxylase enzymes, which break down vaginal peptides resulting in 
malodorous components, especially trimethylamine. It is unknown whether the loss of 
lactobacilli precedes or follows this change in microflora (Sobel 2000). 
 
 
Figure 2 Pathogenesis of bacterial vaginosis  
 
The most successful oral treatment remains metronidazole (500 mg twice daily for 7 days). 
Topical treatment with clindamycine cream (2 % once daily for 7 days) or metronidazole gel 
(0.75 % once daily for 5 days) has shown to be as effective as oral metronidazole (Ferris et al. 
1995). However the recurrence of BV is very high after antibiotic treatment (30 % after 1 
month, 70 % after 3 months). As it is known that lactobacilli can protect against the onset of 
BV, partly by producing lactic acid to maintain a pH of ± 4, probiotic lactobacilli were 
suggested as treatment in patients with BV. Also by the release of H2O2 or bacteriocins, 
lactobacilli inhibit the growth of BV-associated microorganisms (Falagas et al. 2007). 
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Probiotics are defined as living organisms which confer a health benefit to the patient when 
administered in sufficient amounts. 
 
1.3.2.2. Probiotic strain selection 
 
Bacterial strains suitable as probiotic in the treatment or prevention of BV must fulfil specific 
requirements (Reid 2001):  
- good adherence to the vaginal epithelial cells 
- resistant against a large range of bacteriophages 
- resistant against a wide variety of bacteriocins 
- produce a large amount of lactic acid to maintain a low pH as most bacteria are 
inhibited by low pH 
- produce a large amount of H2O2 as hydrogen peroxide has a bactericidal activity 
against most bacteria 
- produce bacteriocins against other species 
 
At the Laboratory for Bacteriology Research (Ghent University Hospital) four strains were 
selected based on these criteria (Saerens 2006): Lactobacillus jensenii PB204-T1-1, 
Lactobacillus crispatus PB125-T1-1, Lactobacillus crispatus PB128-T1-1 and Lactobacillus 
gasseri PB088-T2-1. The L. jensenii strain is a potent producer of H2O2, inhibits the growth 
of pathogenic bacteria and does not inhibit the growth of Lactobacillus species normally 
present in the vagina. The other strains are also strong inhibitors of G. vaginalis and 
Atopobium vaginae and have sufficient H2O2 production. A disadvantage of the L. crispatus 
128 strain is the possible growth inhibition of other Lactobacillus strains.  
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1.3.2.3. Oral versus vaginal delivery 
 
Which administration route is preferable for probiotics remains a matter of debate. In multiple 
clinical trials both administration routes were used, each with their advantages and 
disadvantages. Some research groups advocate the oral route for administration. Morelli et al. 
(2004) demonstrated that oral delivery of Lactobacillus rhamnosus GR-1 and Lactobacillus 
fermentum RC-14 as freeze-dried preparations induced colonisation of the vaginal microflora. 
Moreover, Reid et al. (2004) showed in a randomised, placebo-controlled trial that the 
lactobacilli-dominant microflora was restored in subjects with BV following 2 months of 
daily oral intake of L. rhamnosus GR-1 and L. fermentum RC-14 (> 109 cfu per dose) and 
demonstrated an impact on reducing BV occurrences (prevalence of BV fell from 28 to 4 % 
within the 2-month test period). The mode of action may be multiple, the probiotic strains 
may ascend from the rectum to colonize the vagina, and/or may immunomodulate the host 
leading to a reduction of the vaginal sensitivity to BV pathogens (Reid and Bruce 2003). The 
rectum is assumed as a continuous source for recolonisation of the vagina with bacterial 
strains (Antonio et al. 2005). 
However, the harsh conditions of the gut, including the acidic nature of the stomach and the 
presence of bile in the intestine, adversely affect the viability of probiotic cultures following 
oral consumption. So, only a small fraction of orally administered lactobacilli will survive the 
passage through the gastrointestinal tract and will reach the target viable, which is a 
requirement to exert beneficial effects. Moreover, the time necessary to reach vaginal 
colonisation is delayed as several days are necessary for intestinal passage, vaginal ascension 
and vaginal growth. By vaginal administration of lactobacilli these hurdles are avoided. 
Although oral ingestion may be considered by most women as an easier way of administration 
and although intestinal immunomodulatory events may play a role in the probiotic effect, 
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vaginal administration is a cheaper and more rapid approach to reach high numbers of viable 
lactobacilli in the vagina. The vaginal instillation of L. rhamnosus GR-1 and B-54 or L. 
fermentum RC-14 strains has been shown to reduce the risk of urinary tract infections and to 
improve the maintenance of a normal microflora (Reid and Burton 2002). Finally, topical 
administration avoids organoleptic quality considerations and facilitates development and 
production of the probiotic formulation. 
 
1.4. Stabilisation of bacteria in dry formulations 
 
Preservation of microorganisms by desiccation has been the preferred method for long term 
storage of cultures. The drying process of a bacterial culture can be summarised as presented 
in Figure 3. Each step has an influence on the cell recovery after the drying process (Morgan 
et al. 2006). 
 
Culture micro-organisms 
Mix cells with drying protectant 
Drying process 
Storage 
Rehydration 
Viable cell recovery 
Figure 3 Different steps in the de- and rehydration process of bacterial cultures 
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1.4.1. Growth conditions 
 
The growth medium itself can have an influence on the survival of bacteria after drying. 
Carvalho et al. (2004) showed that the type of carbon source added to the growth medium has 
an influence on the survival ratio after freeze-drying. Bacteria can protect themselves against 
osmotic stress by accumulating compatible solutes in order to maintain the osmotic balance 
between the highly concentrated extracellular environment and the more dilute intracellular 
environment. During a drying process the low water activity can subject the bacteria to 
osmotic stress conditions. Additives (referred as compatible solutes) like polyols and amino 
acids can increase the thermotolerance of bacteria (Kets and de Bont 1996).  
On the other hand also the growth conditions can influence the survival (Desmond et al. 
2002a). If bacteria are grown in stressful conditions (i.e. low pH, high osmotic pressure, high 
or low temperature) the thermotolerance can increase. A stress response from the 
microorganisms can result in the production of stress proteins or in physiological changes of 
the bacterial membrane that increase the tolerance during a drying process (Beales 2004). 
 
1.4.2. External stabilisation 
 
External stabilisation of the culture by the addition of disaccharides, polysaccharides, 
complex drying media and/or vitamins is necessary to obtain an acceptable viability. 
Moreover, the survival is strain dependent: while a stabiliser works very well in a specific 
strain, it can have no beneficial effect during drying of another strain. Two mechanisms of 
stabilisation are known, i.e. glass formation and water replacement (Aguilera and Karel 1997, 
Crowe et al. 1998). A combination of both mechanisms is necessary to obtain good 
stabilisation of bacteria during drying. 
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1.4.2.1. Glass formation 
 
The external stabilisers should form a glassy matrix during drying. If crystallisation occurs 
during drying the formed crystal can damage the cell membrane, compromising the integrity 
of the cell.  
A glass is a supersaturated thermodynamically unstable liquid with a high viscosity, which 
inhibits molecular mobility. Glass formation is characterised by the glass transition 
temperature (Tg). At a temperature above Tg the amorphous material transfers into a rubbery 
state with higher mobility, finally resulting in crystallisation and loss of stabilising capacity. 
At a temperature below Tg the glassy state is maintained. However, for good stabilisation 
storage at a temperature much lower than Tg is required, referred as T0 (zero mobility 
temperature) i.e. at least 50°C below Tg to assure zero mobility (Hatley and Blair 1999).  
The higher the molecular weight of the carbohydrates, the higher the Tg. The glass transition 
temperature is strongly influenced by the water content. By addition of even small amounts of 
water, Tg can decrease under the storage temperature of the product, resulting in collapse, 
followed by crystallisation of the product.  
 
1.4.2.2. Water replacement  
 
Bacterial membranes have a lipid bilayer structure in a liquid crystalline state at physiological 
conditions, in which phospholipids are hydrated with water molecules by hydrogen bonding. 
During drying, water is removed from the bilayer membranes resulting in a higher packing of 
the phospholipid head groups, resulting in loss of structural integrity (Fig. 4). Due to Van der 
Waals interactions the liquid crystalline phase transfers into a gel phase. After rehydration, 
there is a transition of the gel phase to the liquid crystalline phase, with packing deficiencies 
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as result and leaking of the intracellular content. However, small hydrophilic molecules (e.g. 
disaccharides like trehalose) can replace water molecules surrounding the bacterial membrane 
during drying, thereby maintaining the integrity of the membrane in the absence of water.  
 
 
Figure 4 Stabilisation of membranes via water replacement (Crowe et al. 1992) 
 
1.4.2.3. Frequently used stabilisers 
 
Different types of molecules are used as external stabiliser: disaccharides, polysaccharides, 
complex matrices, vitamins, … Some of these are briefly discussed below, their Tg is 
presented in Table 1. 
 
1.4.2.3.1. Lactose 
Lactose is a disaccharide consisting of glucose and galactose bound via β-1,4 bonds (Fig. 5). 
Lactose has a relatively high Tg (105°C) and as it is a small molecule it can replace water 
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molecules during drying and stabilise bacteria via water replacement. Lactose is the main 
carbohydrate in skim milk, a complex matrix which is also often used to stabilise bacteria. 
Zarate and Nader-Macias (2006) used lactose in combination with skim milk and ascorbic 
acid to stabilise probiotic vaginal strains during freeze-drying and storage. For the 
stabilisation of Candida sake Abadias et al. (2001) used different sugars (lactose, trehalose, 
sucrose), polyols (mannitol, sorbitol) and polymers, but the highest survival after freeze-
drying was obtained using a combination of lactose and skim milk. Also Saccharomyces 
cerevisiae was stabilised after freeze-drying by adding lactose to the formulation (Blanquet et 
al. 2005). 
 
 
Figure 5 Chemical structure of lactose 
 
1.4.2.3.2. Trehalose 
Trehalose is a disaccharide consisting of 2 glucose molecules connected via α-1,1 bonds (Fig. 
6). Trehalose has a high Tg (122°C), which is maintained if small amounts of water are added. 
Small amounts of water result in the conversion of the amorphous trehalose into a crystalline 
dihydrate form, thereby shielding the remaining glassy trehalose from a decrease in Tg. 
Because of these characteristics special preservation capacities were attributed to trehalose 
(Crowe et al. 1996). Leslie et al. (1995) achieved a survival of 69.8 % after freeze-drying of 
E. coli using trehalose as stabilising sugar compared to only 8.1 % without trehalose and 56.2 
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% in combination with sucrose. However, more recent work stated that trehalose is not more 
effective than other oligosaccharides. For freeze-drying of Saccharomyces cerevisiae no 
superior survival levels were obtained using trehalose (Blanquet et al. 2005). 
 
 
Figure 6 Chemical structure of trehalose 
 
1.4.2.3.3. Maltodextrins 
Maltodextrins are hydrolysates of starch, with varying molecular weight (Fig. 7). They are 
characterised by their dextrose equivalent (DE) value or degree of hydrolysation (eg. a DE 
value of 38 stands for 38 % hydrolysed starch), hence a high DE value corresponds with a 
lower molecular weight. High molecular weight maltodextrins have a higher Tg, but 
replacement of the water molecules surrounding the bacterial bilayer membranes becomes 
more difficult using maltodextrins with low DE value due to steric hindrance. Andersen et al. 
(1999) showed that maltodextrins with a low DE value better preserved the acidifying activity 
of Streptococcus thermophilus compared to maltodextrins with a high DE value. Boza et al. 
(2004) encapsulated Beijerinckia sp. in maltodextrins via  spray-drying with high survival 
rates after drying and storage. 
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Figure 7 Chemical structure of a maltodextrin 
 
1.4.2.3.4. Skim milk 
Skim milk is a complex mixture consisting of 91.2 % water, 4.9 % carbohydrates (mainly 
lactose), 0.1 % fat, 3.1 % proteins (mainly casein) and 0.7 % minerals and vitamins. The 
stabilising capacity of skim milk during dehydration of bacteria is attributed to its lactose and 
protein fractions. More than 60 % of Lactobacillus rhamnosus GG survived spray-drying 
when skim milk was used as stabilising matrix (Ananta et al. 2005). Zayed and Roos (2004) 
combined skim milk with trehalose and sucrose and obtained a survival of about 85 % after 
freeze-drying of Lactobacillus salivarus. 
 
Table 1 Tg of frequently used stabilisers 
Stabiliser Tg (°C) 
Lactose 105 
Trehalose 122 
Maltodextrin DE 5 188 
Maltodextrin DE 38 100 
Skim milk 72 
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1.4.3. Drying techniques 
 
The drying technique also has a major influence on the bacterial survival. The most 
commonly used drying techniques for bacteria are summarised below. 
 
1.4.3.1. Spray-drying 
 
A solution or suspension is sprayed in hot drying air. Via rapid evaporation of the fluid 
fraction the droplets are dried and the resulting dry powder is collected in a cyclone. Spray-
drying is frequently used in the food industry and is a less expensive and faster process 
compared to freeze-drying. However, due to the high temperatures used in this process (inlet 
air temperature 190-220°C, outlet air temperature 70-120°C), spray-drying is detrimental for 
the survival of bacteria (Metwally et al. 1989; Fu and Etzel 1995). 
 
1.4.3.2. Freeze-drying 
 
Freeze-drying is a drying technique where the solvent is frozen and afterwards removed via 
sublimation (Pikal 1991). Freeze-drying is the most frequently used technique to obtain dried 
bacterial cultures. The lyophilisation process consists of 3 phases, starting with the freezing 
step where the temperature of the shelves is lowered and the product is frozen. During this 
phase a thermodynamically unstable, supercooled solution is formed. Upon ice crystallisation 
the remaining solutes become concentrated and form an amorphous phase. After the freezing 
step the frozen water is removed from the samples via sublimation during primary drying at 
reduced pressure and low temperature. The temperature during primary drying should be 
sufficiently low to prevent that the water molecules have sufficient mobility to induce product 
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collapse. This maximum allowed temperature is characterized by the collapse temperature and 
depends on the formulation. During secondary drying residual (bound) water is removed at 
reduced pressure and higher shelf temperature. As a hygroscopic powder is obtained, further 
handling requires some precautions to assure the quality of the freeze-dried product. Freeze-
drying is a gentle drying process as drying occurs at low temperature, resulting in a high 
survival rate of heat sensitive products like proteins and bacteria (Champagne et al. 1991). 
The most detrimental step is the freezing step and the rate of cooling as the formation of large 
ice crystals can damage fragile cell membranes. As slow cooling yields larger ice crystals this 
problem can be avoided by flash freezing in liquid nitrogen (Morgan et al. 2006). A drawback 
of freeze-drying is the high energy cost and the long duration of the entire process. 
 
1.4.3.3. Layering 
 
Layering is a technique where a solution or suspension is sprayed and subsequently dried on 
inert carriers using a Wurster-based fluidized bed system (Huyghebaert et al. 2005b). 
Fluidized bed layering also occurs at elevated temperature, but is much lower (on average 
about 45°C) than the temperature used during spray-drying. Moreover, this technique results 
in a multi-particulate formulation, whereas spray- and freeze-drying result in a powder that 
must be further processed into a pharmaceutical formulation suitable for oral delivery. A 
multi-particulate pellet formulation assures a fast gastric emptying as it behaves like a liquid 
when it passes through the gastro-intestinal tract (Krämer and Blume 1994). In case of oral 
delivery this is an advantage for gastrosensitive products (such as bacteria) to minimize the 
contact time between gastric acid and layered bacteria. Moreover, the multi-particulate 
formulation can be enterically coated in the same equipment to protect the product against the 
gastric environment. 
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1.4.4. Overview of dried formulations of Lactococcus lactis, Lactobacillus 
jensenii, Lactobacillus gasseri and Lactobacillus crispatus 
 
1.4.4.1. Lactococcus lactis 
 
L. lactis is frequently used in the dairy industry as starter culture. In literature freeze- and 
spray-drying are used in combination with different protective media to obtain dry starter 
cultures for the production of dairy products. 
Broadbent and Lin (1999) used freeze-drying and observed an increase of survival rate after 
drying if L. lactis ssp. cremoris  underwent a 2 h cold shock at 10°C prior to drying: 23 ± 6 % 
survival without cold shock vs. 49 ± 2 % after cold shock. The improved resistance to drying 
was attributed to the presence of cold shock proteins. Similarly Ziadi et al. (2005) showed an 
improvement in survival of L. lactis ssp. lactis after heat treatment for 20 min at 45°C: a 
survival-rate after freeze-drying of 38.8 % for the heat-treated bacteria vs. 21.9 % without 
heat-treatment. To and Etzel (1997) obtained a high survival (63 ± 6 %) after freeze-drying of 
L. lactis ssp. cremoris using a combination of maltodextrins, lactose and phosphate buffer. 
Champagne et al. (1996) used reconstituted skim milk supplemented with gelatin, xanthan 
gum or maltodextrins to improve resistance to freeze-drying of L. lactis ssp. lactis, however 
no significant improvement was shown. Carcoba and Rodriguez (2000) also used 
reconstituted skimmed milk supplemented with different components to improve viability 
after freeze-drying of L. lactis ssp. lactis with the highest viability using β-alanine as 
supplement: a 44.3 % viability using reconstituted skim milk, but 60.7 % if β-alanine was 
added. Doleyres et al. (2004) cultured L. lactis ssp. lactis as an immobilised cell culture using 
κ-carrageenan/locust bean gum gel beads and evaluated the resistance to freeze-drying, 
however no significant improvement in viability compared to a free cell culture was observed: 
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39 ± 16 % and 21 ± 11 %, respectively. Looijestijn et al. (2001) compared the survival after 
freeze-drying of an exopolysaccharide-producing L. lactis ssp. cremoris with a control strain, 
resulting in viabilities of 30.3 and 32.2 %, respectively, indicating that exopolysaccharide 
production did not result in a higher resistance to freeze-drying. Huyghebaert et al. (2005a) 
obtained a viability of 60 ± 18 % after freeze-drying of L. lactis ssp. cremoris using skim milk 
supplemented with glucose and casein hydrolysate. 
Vacuum desiccation of L. lactis showed the highest survival ratio if mannitol was used as 
stabiliser as no loss of viability was reported (Efiuvwevwere et al. 1999). Fu and Etzel (1995) 
used spray-drying for the production of dairy starter cultures of L. lactis ssp. lactis with the 
highest survival percentage of 78 ± 12 % if a high initial cell load (1.1 × 1011 cfu/ml) and a 
low outlet-air temperature of 77°C was used. For L. lactis ssp. cremoris a survival of only 
2.95 ± 0.07 % was obtained using an outlet-air temperature of 65°C (To and Etzel 1997). 
Huyghebaert et al. (2005b) used layering to dry L. lactis on inert carriers obtaining the highest 
viability (9 %) using a combination of skim milk and inulin as stabilising matrix. 
 
1.4.4.2. Vaginal probiotic strains: Lactobacillus jensenii, Lactobacillus gasseri 
and Lactobacillus crispatus  
 
Maggi et al. (1994) freeze-dried L. gasseri using a combination of skimmed milk and malt 
extract as stabilising matrix, yielding in a count of 2.0 × 1010 cfu/g. However, viability 
progressively decreased during storage at 4°C (Maggi et al. 2000). Using the same stabilising 
matrix Mastromarino et al. (2002) obtained viabilities for L. gasseri varying between 9.7 and 
10.7 log cfu/g. Otero et al. (2007) reported a similar viability of this probiotic strain using a 
different matrix (combination of skim milk with sucrose or lactose). 
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Freeze-drying of L. crispatus using skimmed milk and malt extract as stabilising matrix 
resulted in a viability of 7.0 × 107 cfu/g after 1 month storage at 4°C (Maggi et al. 2000), 
whereas Mastromarino et al. (2002) reported a viability of 3.3 × 108 cfu/g immediately after 
freeze-drying using the same stabilisers.  
No literature reports were found about the survival of L. jensenii after drying. 
 
1.5. Gastric protection of orally delivered bacteria 
 
To reach the gastro-intestinal tract bacteria must pass through the detrimental gastric 
environment. To assure that a sufficient dose of bacteria reaches the target site, the 
formulation must be protected against the acidic conditions of the stomach and the bile 
present in the duodenum, indicating that not only viability after drying is important but also 
survival after gastric passage of orally delivered bacterial strains. Klijn et al. (1995) reported 
that only 1 % of Lactococcus lactis survived the human gastro-intestinal tract. In literature 
different approaches are used to obtain enteric protection of a viable bacterial formulation. 
Favaro-Trindade and Grosso (2002) encapsulated L. acidophilus and B. lactis by spray-drying 
using cellulose acetate phthalate as encapsulating agent. Viability of encapsulated bacteria 
decreased with 1 log unit after 2 h at pH 1, whereas non-encapsulated bacteria were 
completely destroyed after 1 h. Desmond et al. (2002b) used acacia gum and skim milk as 
encapsulating agents during spray-drying of Lactobacillus paracasei, with a reduction of 4 
log units after 2 h in porcine gastric juice at pH 3.0. Stadler and Viernstein (2003) prepared 
tablets containing lyophilized L. acidophilus using hydroxypropylmethylcellulose acetate 
succinate (HPMCAS) as matrix forming component. The best result was obtained if a 
combination of HPMCAS and sodium alginate was used, with only 1 log decrease after 2 h in 
0.04 N HCl. At higher HPMCAS concentration gastric protection improved, however 
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disintegration of these tablets was slow when reaching the target site. Calinescu et al. (2005) 
used carboxymethyl high amylose starch as excipient for Escherichia coli oral formulations 
resulting in non-significant differences in viability before and after 2 h incubation in 
simulated gastric fluid. In this case also disintegration problems in simulated intestinal fluid 
were reported. Microencapsulation in calcium alginate beads has been frequently used to 
protect the strains against the gastric environment by creating a physical barrier. 
Chandramouli et al. (2004) reported a 2 log decrease in viability of encapsulated 
Lactobacillus acidophilus after 3 h incubation in simulated gastric conditions (pH 2). Co-
encapsulation of prebiotics (high amylose corn starch, inulin, oligofructose) within alginate 
beads and coating of these calcium alginate capsules with chitosan or poly-L-lysine improved 
protection (Iyer and Kailasapathy 2005, Krasaekoopt et al. 2004). Microencapsulation in a 
casein/pectin complex did not protect at pH values similar to those of the human stomach 
(Oliveira et al. 2007). Encapsulation of bacteria in a whey protein-based microcapsule did 
improve survival in simulated gastrointestinal conditions (Reid et al. 2005, Picot and Lacroix 
2004).  
This brief summary of literature data about enteric protection of bacteria indicates that it is 
difficult to sufficiently protect the tested strains during gastric passage. 
 
1.6. Pellets 
 
Pellets are spherical or nearly spherical, free flowing particles with a narrow size distribution, 
varying between 500 and 1500 µm for pharmaceutical applications (Ghebre-Sellassie and 
Knoch 2002). Often pellets are produced by extrusion/spheronisation, a multi-step process. In 
the first step the different components (excipients and/or API) are dry mixed. This powder 
mix is agglomerated using a granulation liquid, mainly water. The wet mass is extruded 
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through an extrusion screen having die perforations with the desired diameter. The obtained 
cylindrical extrudates are broken into cylindrical rods and rounded into spheres by means of a 
fast-rotating friction plate (Fig. 8). Finally, the pellets are dried, mostly using oven or fluid 
bed drying.  
 
 
 
Figure 8 Dome-extruder and spheroniser used for the production of pellets via extrusion/spheronisation 
 
Microcrystalline cellulose (MCC) is commonly used as the main excipient in 
extrusion/spheronisation. Since microcrystalline cellulose pellets do not disintegrate in 
aqueous media and drug release occurs via diffusion through an insoluble inert matrix, fast 
disintegrating pellets were developed by Dukic et al. (2007) using a specific starch grade 
(UNI-PURE® EX) as main excipient. Pellets are generally used for oral drug delivery of 
API’s, as multi-particulates offer some important pharmacological and technical advantages: 
fast gastric emptying, decreased risk of dose-dumping in case of coated pellets, narrow size 
distribution, free flowing, low friability, ...  
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1.7. Coating/layering of multi-particulate systems 
 
For coating of multi-particulate dosage forms, the Wurster-based fluidized bed system is 
mainly used. The Wurster-based fluidized bed equipment consists of 4 different regions (Fig. 
9) (Christensen and Bertelsen 1997): upbed region, expansion chamber, downbed region and 
horizontal transport region. 
 
 
Figure 9 Wurster based fluidized bed system 
 
The coating process is a three-step process with a start-up phase, coating phase and drying (or 
cooling) phase. During start-up the equipment and circulating product is preheated to the 
desired coating temperature. Preheating prevents over wetting of the product during the initial 
application of the coating solution. Heating also facilitates film formation. During the coating 
phase different processes occur simultaneously. The coating or layering solution is atomised 
through the spray nozzle to form drops with an average diameter of 10-30 µm. These droplets 
are transported to, adhere and dry on the substrate. This process is repeated for each layer 
applied on the product. The solvent evaporation should be controlled in such a way that it is 
Hot air 
Spray nozzle 
Expansion chamber 
Outer cylinder or downbed region 
Inner cylinder or upbed region 
Horizontal transport region or annular zone
Bottom plate
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sufficiently slow to allow dissolution of the first layers to assure a good adhesion of the 
subsequent layers. However, evaporation should not take too long to avoid particle 
agglomeration. After coating, there is a terminal drying or cooling step. 
When using the Wurster setup in a fluid bed, particles make a controlled movement within the 
fluid bed to ensure a homogeneous coating layer on the pellets. A fountain movement is 
created in the fluidisation chamber due to the inner cylindrical tube (upbed region) 
surrounding the spray nozzle and the specific design of the bottom plate (having a higher 
number of perforations in the centre). As a result the air velocity in the inner cylinder is 
higher and particles are transported upwards via the inner cylinder. Simultaneously these 
particles are coated via droplets atomized through the centrally positioned nozzle. In the 
expansion chamber the air velocity drops and particles return via the downbed region where 
the air velocity is lower than the minimum velocity of fluidisation. Clustering of particles 
occurs most frequently in this region. Via the horizontal transport zone product is transported 
in the direction of the upbed region.  
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DEVELOPMENT OF AN ORAL MULTI-
PARTICULATE FORMULATION OF VIABLE 
RECOMBINANT LACTOCOCCUS LACTIS 
 
2.1. Introduction 
 
Layering of multi-particulates (spheres of 1 mm Ø) with bacteria suspended in a stabilising 
matrix was presented as a valuable alternative for the production of a viable Lactococcus 
lactis dosage form (Huyghebaert et al. 2005). However, the bacterial cell load of these layered 
pellets was too low: 36.5 g pellets were required to deliver a single dose of 1011 cfu of L. 
lactis Thy 12, a genetically modified strain producing IL-10 which can be used as a 
therapeutic in the treatment of Crohn’s disease (Van Deventer et al. 1997) and which has 
already been used in an in vivo study (Braat et al. 2006). Hence, the aim of this study was to 
enhance the viability and bacterial cell load of L. lactis Thy 12 on the layered pellets via 
optimisation of several parameters. The influence of process parameters (atomising pressure 
and nozzle diameter) and carrier material (microcrystalline cellulose pellets or starch-based 
pellets) on the viability of L. lactis Thy 12 during layering was evaluated. Different stabilising 
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matrices (skim milk, disaccharides, polysaccharides and polyalcohols) were tested for their 
stabilising capacity and a 1 year stability study was performed. To further increase the amount 
of viable L. lactis Thy 12 on the pellets, the process time and the bacterial cell load in the 
layering suspension were increased. Microencapsulation of bacteria, using sodium alginate as 
encapsulation matrix (Chandramouli et al. 2004), was used as alternative technique to obtain a 
multi-particulate formulation with a high number of viable bacteria. Before the experiments 
the Bioscreen turbidity method, used for the viability assessment, was validated. 
 
2.2. Materials and methods 
 
2.2.1. Materials 
 
Growth media M17 (Difco) and GM17T (i.e. M17 supplemented with 0.5 % glucose and 
50µg/ml thymidine) were purchased from Becton Dickinson (MA, USA). Different stabilising 
matrices were used: skim milk (Difco, Becton Dickinson, MA, USA), lactose (α-Pharma, 
Braine-l’Alleud, Belgium), trehalose (Cerestar, Mechelen, Belgium), sucrose (Federa, 
Brussels, Belgium), isomalt (Cerestar, Mechelen, Belgium), mannitol (Certa, Braine-l’ 
Alleud, Belgium), calcium caseinate (Miprodan®) (Arla Foods Ingredients, Videbaeck, 
Denmark), maltodextrin DE 5 (Glucidex 2, Roquette Frères, Lestrem, France), DE 18 and DE 
38 (Cerestar, Mechelen, Belgium), glucose (Bufa, Uitgeest, The Netherlands), poly vinyl 
alcohol (PVA) (80 and 87 % hydrolyzed) (Sigma-Aldrich, St. Louis, USA), vitamin C (Certa, 
Braine-l’Alleud, Belgium) and chondroitin sulphate (Sigma-Aldrich, St. Louis, USA). 
Microcrystalline cellulose spheres (Cellets®, Pharmatrans-Sanaq, Basel, Switserland) and 
starch-based pellets were used as inert carriers for the layering experiments. Starch-based 
pellets consisted of 7.0 % hydroxypropylmethylcellulose (Methocel® E15, Colorcon, 
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Dartford, UK), 10.1 % sorbitol (Cerestar, Mechelen, Belgium) and 82.9 % starch (Uni-
Pure®EX starch, National Starch and Chemical Company, New Jersey, USA). Sodium 
alginate (Sigma-Aldrich, Steinheim, Germany) and calciumchloride (Merck, Darmstadt, 
Germany) were used for the microencapsulation process. 
 
2.2.2. Bacterial strain 
 
L. lactis Thy 12 (human IL-10 producing L. lactis subsp. cremoris MG1363 derivate) was 
obtained from the Department of Molecular Biomedical Research (Ghent University, 
Belgium). L. lactis is a non-pathogenic, non-invasive, Gram-positive lactic acid bacteria 
generally used to produce fermented dairy products. L. lactis Thy 12 was genetically modified 
in order to produce human IL-10 and was made thymidine dependent to avoid spreading of 
the bacteria in the environment (Steidler et al. 2003).  
The bacteria were stored at -20°C as a stock suspension in glycerol/GM17T (50/50). 
 
2.2.3. Validation of the viability assessment method using the Bioscreen 
turbidity method 
 
Growth media were sterilised using a simple stovetop autoclave (Presto® pressure canner 23 
Quart, Eau Claire, Wisconsin, US). Sterilised growth media were stored at 4°C for maximum 
1 week before use. The growth media were acclimatised to room temperature before each 
experiment. Before the onset of a new experiment membrane-sterilised glucose and thymidine 
were added to the growth medium. 
Viability of the bacteria after processing was determined by monitoring the growth of 
standards and samples in a Bioscreen-C (Labsystem, Helsinki, Finland) via optical density 
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measurements. Different dilutions (13 in total) of the overnight culture were prepared, using 
fresh GM17T as diluents and loaded in triplicate into microtiter plates for analysis in the 
Bioscreen. The growth at 30°C was monitored over 24 h. Based on the exponential growth 
phase, the time necessary to reach an optical density at 600 nm (OD600) half way the 
minimum and maximum OD600 (50 % time) was calculated (Fig. 1). The 50 % time was 
plotted against the natural logarithm of the viability to calculate the equation of the standard 
curve (Fig. 2). The viability of a sample was determined based on the standard curve of the 
overnight culture and expressed as percent survival of the overnight culture. For each drying 
experiment a new calibration curve was made, as the number of bacteria obtained in the 
stationary phase was not identical for each culture.  
To evaluate the effect of sample preparation on viability, layered pellets were vortexed for 10, 
30 or 60 s in 1 or 10 ml sterilised water to release the bacteria from the matrix. Three dilutions 
of each sample were loaded in duplicate into microtiter plates for analysis in the Bioscreen.  
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Figure 1 Example of growth curves of 40% dilutions of the starting culture and visualisation of the method used 
to determine T50% 
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Figure 2 Example of a standard curve (T50% against the natural logarithm of the viability) 
 
To evaluate the day-to-day variability of the method pellets layered with L. lactis were 
analysed on 6 different days using a single batch of growth medium. To evaluate the influence 
of the sterilising process on the viability, growth medium autoclaved for 15 (standard process 
time) or 60 min was used during analysis of a sample via the Bioscreen method.  
 
2.2.4. Preparation of the layering suspensions 
 
L. lactis Thy 12 cultures were prepared by inoculating the stock suspension 1/1000 in GM17T 
growth medium. The culture was grown for 16 h at 30°C to reach the stationary phase (2-3 × 
109 cfu/ml) (ON culture). The bacteria were collected by centrifugation at 3000g for 20 min at 
4°C. The cell pellet was resuspended at 2-3 × 1010, 6-9 × 1010 or 1-1.5 × 1011 cfu/ml 
(respectively 10-, 30- and 50-fold concentrated compared to ON culture) in different layering 
matrices (Table 1).  
To prevent further activity or growth, the cultures were kept on ice in between all handling 
steps. 
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Table 1 Overview of different layering matrices 
Stabilising matrix Concentration (w/v) 
Influence of stabilising matrix 
Skim milk 
Lactose 
Ca-caseinate 
Lactose/Ca-caseinate 
Trehalose 
Sucrose 
Isomalt 
Mannitol                Polyalcohol 
Maltodextrin DE 5 
Maltodextrin DE 18 
Maltodextrin DE 38 
Glucose 
PVA (80% hydrolyzed) 
PVA (87% hydrolyzed) 
Lactose/vitamin C 
Chondroitin sulphate 
Influence of stabiliser/bacteria ratio 
Skim milk 
Lactose 
Trehalose 
Longer process time 
Lactose 
Lactose/maltodextrin DE 5 
Lactose/skim milk 
Higher bacterial cell concentration in layering suspension 
Lactose/skim milk 
 
10 % 
5 % 
3.8 % 
5/3.8 % 
5 % 
5 % 
5 % 
5 % 
5 % 
5 % 
5 % 
5 % 
5 % 
5 % 
5 %/1.25 % 
5 % 
 
5 % - 10 % - 20 % 
2.5 % - 5 % - 10 % 
2.5 % - 5 % - 10 % 
 
5 % 
5/2.5 % - 5/5 % 
5/10 % 
 
5/10 % - 10/20 % 
Skim milk and components 
Disaccharides 
Polysaccharides 
Synthetic polymers 
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2.2.5. Evaluation of the influence of atomising pressure and nozzle diameter on 
viability 
 
A layering suspension consisting of L. lactis Thy12 (2-3 × 1010 cfu/ml) in 10% skim milk was 
atomised at different pressures (0.5, 1.5 and 2 bar) and through different nozzles (Ø 0.8 and 
1.2 mm) using a fluid bed (GPCG 1, Glatt, Binzen, Germany). The atomised suspensions 
were collected and analysed for viability using the Bioscreen turbidity method. 
 
2.2.6. Layering process (n = 3) 
 
Microcrystalline cellulose spheres (Cellets®) and starch-based pellets were used as inert 
carriers. Equal amounts of Cellets® 700 (700-1000 μm) and Cellets® 1000 (1000-1250 μm) 
were mixed to obtain 300 g pellets. Starch-based pellets (900-1400 μm) were produced by 
extrusion/spheronisation (Dukic et al. 2007). Layering was performed in a fluid bed apparatus 
(GPCG 1, Glatt, Binzen, Germany) used in the bottom spray mode with the Wurster setup 
(nozzle diameter 0.8 mm, spray rate 3 g/min, product temperature 45°C, air velocity 7-8 m/s, 
process time 30 min, atomising pressure 1.5 or 2 bar, inlet air relative humidity 20 %). During 
layering the layering suspension (containing bacteria and stabilising matrix) was kept on ice. 
A stability study was performed for the 10 % skim milk and the 5 % trehalose, lactose, 
sucrose and isomalt matrices. The pellets were packed in Alu sachets (LPS, Vapor flex barrier 
bag, NJ, USA) and sealed at 20 % RH. The sachets were stored for 12 months at 8°C and -
20°C and viability was assessed after 1, 3, 6 and 12 months. 
To predict the sensitivity of the bacteria to a longer process time, the pellets layered for 30 
min were incubated for 2 h at 45°C and a relative humidity of 20 %. The pellets were 
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evaluated for viability immediately after layering and after an incubation time of 30, 60, 90 
and 120 min. 
 
2.2.6.1. Evaluation of the pellets 
 
Viability of the bacteria after layering was determined by the Bioscreen turbidity method 
(paragraph 2.2.3). 0.1 g of the layered pellets was vortexed for 30 s in 1 ml sterile water to 
release the bacteria from the layered pellets. Some samples were evaluated for viability using 
the plate count method. Via the pour plate method a dilution series of the samples was plated 
out using GM17T/agar as growth medium and after 48 h incubation at 30°C the colony 
forming units were counted. 
 
2.2.7. Dynamic vapour sorption 
 
Water sorption isotherms of the layered pellets were determined gravimetrically at 25 ± 0.1°C 
using a DVS Advantage 1 with a Cahn D200 microbalance (Surface Measurement Systems, 
London, UK). Between 10 and 20 mg pellets were placed in the sample cup of the instrument, 
subjected to a drying step in order to bring the sample to a constant weight and subsequently 
exposed to increasing relative humidity (RH) (using 10 % increments up to 90 % RH). Each 
step continued until equilibrium was reached (i.e. when the change of mass was smaller than 
0.002 % per minute during at least 10 min). The mass change was recorded every minute with 
a resolution of ± 0.1 µg. 
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2.2.8. Microencapsulation process 
 
Bacteria of an overnight culture were collected by centrifugation and resuspended in a 2 % 
sodium alginate solution, enriched with 5 % lactose or 5 % trehalose. Microencapsulation of 
the bacteria was performed using syringe and needle (diameter: 1.1 mm) via drop wise 
addition of the sodium alginate/bacteria suspension to a 0.1 M calcium chloride solution, 
which was continuously stirred using a magnetic stirrer. The capsules were allowed to stand 
for about 10 min for hardening and were then collected by filtration. The capsules were 
washed with distilled water. The obtained microcapsules were freeze-dried using an Amsco 
Finn Aqua GT4 freeze-dryer (Amsco, Germany). The capsules were flash frozen to -70°C via 
immersion during 1 min in liquid nitrogen or frozen to -45°C within 175 min (by placing the 
samples on the shelf of the freeze-drier). Primary drying was performed at -15°C and a 
pressure varying between 0.8 and 1 mbar during 13 h, followed by secondary drying at 
elevated temperature (10°C) and reduced pressure (0.1–0.2 mbar) for 7 h. In one experiment a 
48 h freeze-drying process was used. 
 
2.2.8.1. Evaluation of the microcapsules 
 
Microcapsules were evaluated immediately after production, after the liquid nitrogen freezing 
step and after freeze-drying. 100 mg microcapsules were stirred for 30 min in 0.1 M sodium 
citrate solution to release the bacteria from the microcapsules. After 30 min samples were 
collected and analysed by the Bioscreen turbidity method or the plate count method. 
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2.2.9. Statistical analysis 
 
The viability values were statistically evaluated with a one-way ANOVA or an independent 
sample T-test at a significance level of 0.05. The normality of the data was checked by means 
of a Kolmogorov-Smirnov test and the homogeneity of the variances by means of a Levene 
test. A multi comparison among pairs of means was performed using a Scheffé test with p < 
0.05 as significance level. All analyses were performed with SPSS 12.0 for Windows. 
 
2.3. Results and discussion 
 
2.3.1. Validation of the Bioscreen turbidity method 
 
To evaluate the survival of bacteria after drying an appropriate viability measurement 
technique should be used. Although different methods are available for the viability 
assessment of bacteria (Caldwell 1995), the most commonly used technique is the plate count 
method. A quantitative dilution of a bacterial suspension is prepared and distributed within or 
on the surface of an agar plate and incubated for 1-2 days at the ideal temperature. After 
incubation the colony forming units (cfu) are counted and multiplied by the according dilution 
factor, to enumerate the number of viable cells in the original sample. As this technique is 
time consuming and quite large standard deviations are obtained, an alternative technique was 
used in this work.  
Growth of bacteria can be monitored via turbidity of a bacterial cell culture and the 
Bioscreen-C apparatus (Begot et al. 1996) specifically allows to automatically monitor the 
bacterial growth of several samples using a microwell plate maintained at the required growth 
temperature. Via this apparatus the growth is followed via turbidity measurements in function 
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of time. Samples need to be shaken before each turbidity measurement to ascertain a 
homogeneous mixture. In this research work the Bioscreen turbidity method is used to assess 
the bacterial survival rate after processing based on the growth rate of the bacteria. At the start 
of the study the assessment of viability via the Bioscreen turbidity method was validated.  
As bacteria were released from the layered pellets using vortex mixing in sterilised water, the 
influence of vortex time and dissolution volume on the viability was measured. However, 
viability did not depend on these variables (Table 2). For all experiments during this project 
the vortex time was set at 30 s in a dissolution volume of 1 ml. 
 
Table 2 Viability ± SD (%) after 10, 30 or 60 s vortexing of layered pellets in 1 or 10 ml sterile water 
Vortex time (s) Dissolution volume (ml) Viability (%) 
10 1 8.2 ± 0.5a 
30 1 8.1 ± 0.1a 
60 1 8.0 ± 0.1a 
30 10 9.1 ± 0.7a 
a Groups with the same superscript are not significantly different (p>0.05) (one-way ANOVA, post hoc Scheffé) 
 
The day-to-day variability of a sample analysed via the Bioscreen method on 6 consecutive 
days using the same batch of growth medium was limited: the overall mean viability was 20.1 
% with a coefficient of variation of 5.4 %. 
During sterilisation the quality of a growth medium can decrease due to the high temperature 
causing degradation of sugars and proteins (Wang and Hsiao 1995). It was obvious that the 
quality of the growth medium had a significant influence on the viability of a sample: growth 
medium autoclaved for 15 min resulted in a viability of 20.1 ± 1.1 %, whereas medium 
sterilised for 1 h resulted in a viability of only 10.2 ± 1.3 % for the same sample. The 
measured OD50% for a sample not only depended on the number of viable bacteria in the 
sample, but also on the quality of the growth medium used.  
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The influence on viability using different batches of sterilised M17 was assessed by analysing 
a sample on 5 different days using a new batch of sterilised growth medium for each analysis. 
Similar results were obtained on each day: the overall mean was 21.0 % with a coefficient of 
variation of 7.1 %.  
 
2.3.2. The layering process 
 
2.3.2.1. Influence of atomising pressure, nozzle diameter, inert carrier and 
stabilising matrix 
 
The viability of Lactococcus lactis Thy 12 after atomisation at different pressures through 
different nozzles was not significantly different from 100 % at each condition tested. It can be 
concluded that the shear stress caused by atomisation did not influence the viability of L. 
lactis Thy 12. Fu and Etzel (1995) reported no loss in survival after atomisation of a L. lactis 
C2 strain, and concluded that atomisation alone did not appear to cause cellular injury. Also, 
the type of inert carrier had no influence on the viability of L. lactis after layering as there was 
no significant difference in viability between the MCC pellets and the starch-based pellets 
using a 5 % trehalose or lactose matrix: 6.7 ± 1.3 % and 6.3 ± 1.1 % respectively, for 
trehalose and 8.9 ± 1.7 % and 7.8 ± 1.6 % for lactose (Fig. 3).  
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Figure 3 Viability (mean ± SD) of L. lactis Thy 12 after 30 min layering in different matrices on different inert 
carriers (n= 3). (a) Groups with the same superscript within the same stabilising matrix are not significantly 
different (p>0.05) (independent sample T-test) 
 
Since the effect of stabilisers on the viability depended on the bacterial strain and the drying 
technique (Hubalek 2003), several polyols (disaccharides, polyalcohols, polysaccharides), 
PVA and a skim milk medium (10 % w/v; consisting of 5 % lactose, 3.8 % proteins (mainly 
Ca-caseinate), 0.1 % fat, minerals and vitamins in water) were evaluated for their stabilising 
capacity of L. lactis Thy12 during layering on inert MCC carriers.  
The viability of L. lactis Thy 12 after layering in a 10 % (w/v) skim milk suspension was 3.1 
± 1.2 %. To evaluate the stabilising capacity of each individual milk component, L. lactis Thy 
12 was layered in a 5 % lactose and 3.8 % Ca-caseinate suspension, resulting in a 
significantly higher (8.9 ± 1.7 %) and lower viability (0.7 ± 0.2 %), respectively (Fig. 4). A 
better stabilisation of bacteria using lactose alone instead of skim milk was also found during 
freeze-drying by Costa et al. (2000). Probably Ca-caseinate, due to its high molecular weight, 
inhibited direct interaction of lactose with bacterial membranes. Small molecules, like 
disaccharides, can replace the water molecules surrounding the phospholipids groups of the 
bacterial membranes during drying, preventing collapse of the membrane (Crowe et al. 1998). 
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The negative influence of Ca-caseinate on the stabilising capacity of lactose after layering was 
confirmed by adding 3.8 % Ca-caseinate to a 5 % lactose solution which resulted in a 
significant decrease in viability (0.3 ± 0.1 %). 
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Figure 4 Viability (mean ± SD) of L. lactis Thy 12 after 30 min layering in different stabilising matrices (n= 3). 
(a-c) Groups with the same superscript are not significantly different (p>0.05) (one-way ANOVA, post hoc 
Scheffé) 
 
Comparison of the viability in matrices containing other disaccharides revealed that the 
viability of L. lactis, suspended in a 5 % trehalose, isomalt and sucrose matrix was not 
significantly different from that in a 5 % lactose matrix (Fig. 5). However, the isomalt and 
sucrose matrices resulted in sticking problems during layering. Trehalose, known as the 
golden standard for stabilisation during anhydrobiosis (Crowe et al. 1996), did not result in a 
better stabilisation after layering. Although Efiuvwevwere et al. (1999) reported a high 
viability after drying of L. lactis using mannitol as stabiliser, this was not confirmed in our 
study since layering in a 5 % mannitol matrix did not provide protection, probably due to 
crystallisation of mannitol.  
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Figure 5 Viability (mean ± SD) of L. lactis Thy 12 after 30 min layering in different matrices (5 %) (n=3)  
 
Layering of L. lactis in a solution of maltodextrins (polysaccharide) with a higher DE (i.e. 
higher degree of hydrolysis) resulted in a significantly higher viability compared to the lower 
DE maltodextrins (Fig. 5). However, the viability was much lower compared to that in 
disaccharide matrices. It was concluded that incorporation of L. lactis in an amorphous 
maltodextrin matrix was not sufficient for stabilisation during fluid bed layering. The higher 
molecular weight maltodextrins are probably not able to directly interact with the membranes 
of the bacteria because of steric hindrance (Ananta et al. 2005). Completely hydrolysed starch 
(i.e. 5 % glucose) resulted in a significantly lower viability of 1.38 ± 0.59 %, compared to 
MD DE 38 (Tg 67-73°C), probably because of its low Tg (21-39 °C). At a temperature below 
Tg the material is in a glassy state of high viscosity, inhibiting chemical and biochemical 
reactions as the mobility in this state is very low. At a storage temperature above Tg, the 
material will enter a rubbery state with a lower viscosity and loss of stabilising capacity. 
Moreover, layering of a glucose solution resulted in sticking problems.  
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Layering of the bacteria in synthetic polyvinyl alcohol matrices resulted in low viabilities 
(Fig. 5). Although Deaker et al. (2007) showed stabilization of rhizobia using synthetic 
polyvinyl alcohol matrices (with the highest survival for an intermediate hydrolysed form of 
PVA), layering using different PVA grades could not protect L. lactis during layering. 
Peptidoglycan is an essential and specific component of the bacterial cell wall found on the 
outside of the cytoplasmic membrane of almost all bacteria. The main function of 
peptidoglycan is to preserve cell integrity. Peptidoglycan consists of glycan strands cross-
linked by short peptides. The glycan strands consist of alternating N-acetylglucosamine and 
N-acetylmuramic acid (Vollmer et al. 2008). Chondroitin sulphate is a sulphated 
glucosaminoglycan composed of alternating N-acetylgalactosamine and glucuronic acid. 
Chondroitin sulphate is one of the main compounds of the extracellular matrix and it serves to 
assure the integrity of the surrounding tissues (Monfort et al. 2008). As there is a similarity 
between the chemical structure of peptidoglycan and chondroitin sulphate (Fig. 6) it was 
evaluated if chondroitin sulphate can protect L. lactis during drying. However, after layering 
with 5 % chondroitin sulphate a viability of only 0.15 % was achieved. 
 
 
a 
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b  
Figure 6 (a) chondroitin sulphate and (b) peptidoglycan structure 
 
Vitamin C as anti-oxidant can be added as an additional stabilizer in combination with sugars 
to improve the bacterial survival after drying (Champagne et al. 1991). Addition of 1.25 % 
vitamin C to a 5 % lactose matrix resulted in a low viability (< 1 %) and sticking problems 
were observed during processing. 
 
During layering in a conventional fluidized bed system, particles reside mainly in the annular 
zone (Fig. 7). Since particles can become overheated in this zone, which would decrease the 
bacterial survival, El mafadi et al. (2005) developed a modified fluidized bed system, where 
hot air only passed through the centre of the bottom plate. When a conical disk was placed 
over the outer cylinder of the bottom plate, they observed no influence on particle movement 
and a decrease in temperature in the annular region.  
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Figure 7 Schematic representation of the Wurster coating process with (a) the conventional equipment (b) 
modified equipment (El Mafadi et al. 2005) 
 
However, modifying the fluid bed used in this study by placing an insert over the bottom plate 
(Fig. 8) did not improve the viability using 5 % trehalose as stabilising matrix: after 30 min 
layering a viability of 6.7 ± 1.3 % was obtained for the conventional system and 4.8 ± 0.3 % 
for the modified system (Fig. 9). 
a         b 
   
Figure 8 Bottom device of the Wurster-based fluid bed with (a) the conventional equipment (b) modified 
equipment 
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Figure 9 Viability (mean ± SD) of L. lactis Thy 12 after 30 min layering in a conventional and modified fluid 
bed  (n= 3) using 5 % trehalose as stabilising matrix.  
 
To evaluate the influence of the stabilizer/bacteria ratio on the viability of L. lactis the 
concentration of skim milk, lactose and trehalose in the layering matrix was varied. Varying 
the skim milk concentration from 5 to 20 % did not result in a significant difference in 
viability after layering (Fig. 10). For the trehalose and lactose matrix a higher 
stabilizer/bacteria ratio resulted in a higher viability, but no significant difference was 
observed between 5 and 10 %.  
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Figure 10 Viability (mean ± SD) of L. lactis Thy 12 after 30 min layering in different matrices at different 
stabiliser/bacteria ratios (n=3). (a,b) Groups with the same superscript within the same stabilising matrix are not 
significantly different (p>0.05) (one-way ANOVA, post hoc Scheffé) 
  
63
Chapter 2 
To assure accurate dosing of these therapeutic IL-10 producing bacteria, a reproducible 
viability of L. lactis is required. Therefore, it was evaluated if the viability could be 
maintained during storage. The pellets layered with 10 % skim milk, 5 % lactose, trehalose, 
isomalt and sucrose were stored at low relative humidity (20 %) and a temperature of 8°C or -
20°C (Fig. 11). Whereas storage for 1 month at 8°C already resulted in a significant decrease 
in viability (except for the 5 % sucrose matrix), there was no significant decrease in viability 
of all matrices after 12 months storage at -20°C (except for the 5 % isomalt matrix).  
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Figure 11 Viability (mean ± SD) of L. lactis Thy 12 after layering and after 1, 3, 6 and 12 months storage in Alu 
sachets (sealed at 20 % RH) at 8 or -20°C. (a-c) Groups with the same superscript within the same stabilising 
matrix are not significantly different (p>0.05) (one-way ANOVA, post hoc Scheffé) 
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2.3.2.2. Increasing the bacterial cell load on the pellets 
 
From the above shown data it is clear that the bacterial viability in the layered pellets was low 
(max. about 10 %) independent of the matrix. To increase the load of viable bacteria on the 
pellets a longer process time and a higher bacterial load in the layering suspension were 
evaluated for a formulation containing 5 % lactose. Increasing the process time from 30 to 
120 min reduced the viability from 9.6 ± 1.7 % after 30 min to 2.9 ± 0.9 % after 120 min. 
Moreover, sticking of the pellets occurred after 1 h processing. These observations are 
probably due to crystallisation of lactose during the layering process, damaging the bacterial 
cell membrane. To inhibit lactose crystallisation, different stabilisers were added to the 
lactose matrix (maltodextrins and skim milk). To evaluate which components could inhibit 
lactose crystallisation, a 2 h process time was simulated by layering the pellets for 30 min 
followed by a 2 h incubation period at 45°C (= process temperature). Incubation of layered 
pellets with 5 % lactose as stabilising matrix during 2 h significantly decreased the viability 
(2.8 ± 0.9 % after 120 min) (Fig. 12). However, this confirmed that incubation can be used as 
predictive tool since a similar viability was determined after 2 h processing in a fluid-bed (2.9 
± 0.9 %). Adding 5 % MD DE 5 to the 5 % lactose solution resulted in a significantly lower 
viability after 30 min layering (2.5 ± 0.7 %), although the viability was maintained during 2 h 
incubation. Lowering the MD DE 5 concentration to 2.5 % increased the initial viability (6.7 
± 1.1 %), but this higher value could not be maintained during incubation at 45°C. A 
combination of 5 % lactose and 10 % skim milk resulted in a viability of 7.8 ± 1.2 % 
immediately after layering, which was not significantly different from the viability of the 5 % 
lactose matrix alone, but significantly different compared to a 10 % skim milk matrix (3.1 ± 
1.2 %) as the higher lactose/protein ratio allowed more interaction between lactose and 
bacterial membranes. Furthermore, there was no significant decrease in viability after 2 h 
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incubation at 45°C. Joupilla and Roos (1994) proposed as hypothesis that the proteins in skim 
milk protected lactose from crystallisation. 
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Figure 12 Viability (mean ± SD) of L. lactis Thy 12 after layering and subsequent incubation at 45°C for 30, 60, 
90 and 120 min in Alu sachets (sealed at 20% RH) (n=3) 
 
To confirm these predictive results, the 5 % lactose/10 % skim milk matrix was selected for a 
2 h layering process, resulting in a viability of 10.9 ± 1.6 % after 2 h. This relative viability 
corresponds with an absolute number of 3.6 × 108 cfu/100 mg pellets. No technical problems 
were encountered during the process.  
 
To further increase the bacterial cell load on the pellets a layering suspension with a higher 
concentration of bacteria was used. 5 % lactose/10 % skim milk was used as stabilizing 
matrix when the cell concentration in the layering suspension was increased from 2-3 × 1010 
(10-fold concentration of overnight culture) to 1-1.5 × 1011 cfu/ml (50-fold concentration of 
overnight culture). The viability dropped significantly (from 7.8 ± 1.2 % to 1.6 ± 0.3 %) when 
the layering suspension was more concentrated (Fig. 13). However, when the concentration of 
stabilising matrix was increased (10 % lactose/20 % skim milk) the viability of the 
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concentrated suspension could be maintained during processing: 13.5 ± 3.6 % and 13.6 ± 0.5 
% for a 10- and 50-fold concentrated suspension, respectively.  
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Figure 13 Viability (mean ± SD) of L. lactis Thy 12 after 30 min layering in function of bacterial concentration 
and stabilising matrix/bacteria ratio (n=3). (a,b) Groups with the same superscript within the same stabilising 
matrix are not significantly different (p>0.05) (one-way ANOVA, post hoc Scheffé) 
 
This 10 % lactose/20 % skim milk matrix was also suitable for a 2 h layering process, as a 30-
fold concentrated suspension yielded a viability of 13.9 ± 1.7 %. Via this approach the 
number of viable L. lactis on the pellets could be increased as this relative viability 
corresponded to an absolute number of viable bacteria of 1.7 × 109 cfu/100 mg pellets. To 
administer a dose of 1011 cfu, an acceptable amount of 6 g pellets should be taken. After 12 
months storage of these pellets at -20°C no significant decrease in viability was observed. 
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2.3.2.3. Dynamic vapour sorption 
 
It was hypothised that stabilisation of the bacteria in the lactose/skim milk matrix was partly 
due to the amorphous state of the sugar layer. As the sugar layer was too thin to use 
differential scanning calorimetry or X-ray diffraction to determine the crystallinity, DVS was 
used as alternative technique. When the relative humidity was increased from 55 to 65 % a 
sudden weight drop was observed due to water loss (Fig. 14). As water sorption below 55 % 
RH plasticised the amorphous regions of the matrix the glass transition temperature decreased 
which allowed sufficient molecular movement to initiate crystallisation of the amorphous 
regions (Buckton and Darcy 1995). During crystallisation the excess of water is expelled from 
the sample. Since in the isothermal sorption plot of the unlayered MCC pellets, no 
crystallisation process was observed, the decrease in mass originated from the sugar layer on 
the pellets. This DVS plot confirmed that the applied lactose/skim milk layer contained 
amorphous regions which offered protection to the bacteria (Crowe et al. 1998). 
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Figure 14 DVS isothermic sorption curve of lactose/skim milk layered and inert pellets 
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2.3.3. Microencapsulation process 
 
Although immediately after encapsulation there was no loss of bacteria (110.8 ± 14.2 %), only 
0.17 % of the bacteria survived the freeze-drying process if only sodium alginate was used as 
encapsulation polymer. To increase the viability after drying 5 % lactose or trehalose were 
added to the sodium alginate solution to stabilize the encapsulated bacteria during drying. 
Immediately after encapsulation no loss in viability was found under these conditions. After 
drying 11.7 ± 4.7 % of the bacteria remained viable in the lactose-stabilised microcapsules 
and 8.1 ± 3.1 % in the trehalose-stabilised capsules. Via the plating out method an absolute 
number of viable bacteria of respectively 6.6 × 108 cfu and 1.2 × 109 cfu per 100 mg 
ental effect on the 
ash frozen using liquid nitrogen. Immediately after 
eezing of the lactose- and trehalose-stabilised capsules, 53.5 ± 6.0 % and 49.9 ± 10.8 %, 
respectively, of the bacteria were viable. After drying the viability was about 10 % for both 
freezing. In order to assure that, during microcapsule hardening, there was no loss of stabiliser 
2 
concentration in the CaCl2 solution. This resulted in an absolute bacterial load of 9.7 × 10  cfu 
and 1.1 × 10 cfu/100 mg, which is similar to the experiment without stabiliser in the 
molecules. The number of viable bacteria in the microcapsules was equal to the layered 
A longer freeze-drying process did not result in a better microcapsule quality. 
microcapsules was measured. To verify if the freezing rate had a detrim
bacterial viability, microcapsules were fl
fr
type of microcapsules, indicating that the survival rate could not be improved via immediate 
due to diffusion into the CaCl solution, lactose and trehalose were also added in a 5 % 
8
9 
hardening solution. There was no difference between lactose and trehalose as stabilising 
pellets. However, the obtained microcapsules were very brittle and sticky to handle (Fig. 15). 
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Figure 15 Microcapsules before drying (left) and after drying (right) 
 
2.4. Conclusion 
 
By changing the stabilising matrix, process time and bacterial cell concentration in the 
layering suspension a layered formulation of L. lactis Thy 12 with an acceptable load of 
bacteria on the pellets could be obtained, as a dose of 6 g pellets corresponded with 1011 cfu. 
The formulation can be stored for at least 12 months at -20°C without a decrease of viability. 
This layering technique can also be used to stabilise other types of bacteria or proteins, but 
every bacterial strain and protein will behave differently during drying and storage. However, 
a drawback of this technique is the storage requirement at -20°C as it is essential to maintain 
the cold chain during the entire life cycle of the product. Microencapsulation did not result in 
n acceptable multi-particulate formulation for the bacterial strain under evaluation. a
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ENTERIC PROTECTION AND ILEUM 
TARGETING OF A LAYERED PELLET 
FORMULATION 
 
3.1. Introduction 
 
In the previous chapter layering of pellets was presented as a valuable technique for the 
production of a viable L. lactis dosage form. This multi-particulate dosage form offered 
several advantages: (a) layering and enteric coating (required due to the sensitivity of L. lactis 
to gastric fluids (Klijn et al. 1995)) can be performed in the same equipment; (b) the small 
particle size of the pellets assures fast gastric emptying of the formulation, limiting the 
contact time with the gastric environment (Krämer and Blume 1994); (c) ease of 
administration since small particles can be easily swallowed or mixed with food. In this 
chapter the gastric resistance of the layered bacteria was improved using an enteric polymer in 
combination with different subcoatings. As Crohn’s disease is mostly occurring in the ileal 
part of the intestine, the ileum targeting capacity of the coating polymer was assessed using 
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different coating thicknesses. In another approach the enteric polymer Eudragit® FS30D was 
chemically modified to achieve ileum targeting. 
 
3.2. Materials and methods 
 
3.2.1. Materials 
 
As coating polymer, a 30 % (w/w) aqueous Eudragit® FS30D dispersion (Röhm, Darmstadt, 
Germany) was used in combination with polysorbate 80 (wetting agent) (Tween 80, Alpha 
Pharma, Nazareth, Belgium) and glycerol monostearate (glidant) (Federa, Braine-l’ Alleud, 
Belgium). Sureteric® (Colorcon, Kent, UK) was also used for enteric coating. HPMC-based 
(Opadry®) (Colorcon, Kent, UK) or PVA-based polymers (Opadry® II and Opadry® AMB) 
(Colorcon, Kent, UK) were used as subcoatings before enteric coating. Microcrystalline 
cellulose spheres (Cellets®, Pharmatrans-Sanaq, Basel, Switserland) were used as inert 
carriers for the layering and coating experiments. Thymidine (Alkemi, Lokeren, Belgium) and 
microcrystalline cellulose (Avicel® PH 101, FMC Europe, Brussels, Belgium) were used for 
the production of the marker pellets. 
 
3.2.2. Enteric coating and subcoating of the layered pellets 
 
Layered pellets were enterically coated with Eudragit® FS30D (aqueous dispersion of an 
anionic copolymer based on methyl acrylate, methyl methacrylate and methacrylic acid) or 
subcoated with an HPMC-based (Opadry®) or PVA-based coating (Opadry® II and Opadry® 
AMB) before enteric coating (Fig. 1). 
 
76
Enteric protection and ileum targeting of a layered pellet formulation 
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enteric coating 
 
 
Enteric coated with Eudragit® 
FS30D 
Figure 1 Flow-chart for layering, subcoating and coating of the pellets 
 
For preparation of the Eudragit® FS30D coating dispersion polysorbate 80 and glycerol 
monostearate were added to water and stirred for 10 min with a high-shear mixer (Silverson, 
Bucks, United Kingdom) until a fine, homogenous dispersion was obtained. This dispersion 
was gently added to the Eudragit® FS30D dispersion and mixed using magnetic stirring. The 
coating dispersion was passed through a 0.3 mm sieve before use. Throughout the coating 
process the coating dispersions were stirred. 300 g pellets (Cellets®) were coated in a fluid 
bed coating apparatus (GPCG1, Glatt, Binzen, Germany), used in the bottom spray mode with 
Wurster setup (nozzle Ø 0.8 mm). Before coating, the pellets were preheated to the required 
product temperature. Pellets were enterically coated with Eudragit® FS30D until a polymer 
weight gain of 5, 10 or 15 % was reached. After coating, the pellets were packed in Alu 
sachets sealed at 20 % RH and stored at -20°C.  
Sureteric® coating dispersion (mixture of polyvinyl acetate phthalate, plasticisers and other 
processing ingredients) was prepared by gently adding the powder to water on a magnetic 
stirrer until a 15 % dispersion was obtained. To prevent foam formation a simethicone 
emulsion was added in a concentration of 0.33 % of the polymer dry weight.  
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To prepare the subcoating dispersions, the powders were gently mixed with water using a 
magnetic stirrer, until a 10 % dispersion was achieved for Opadry® and a 15 % dispersion for 
Opadry® II and Opadry® AMB. Pellets layered with L. lactis Thy 12 (in 10 % lactose/20 % 
skim milk as matrix) were subcoated with 4 % Opadry®, Opadry® II and Opadry® AMB prior 
to enteric coating. The coating and subcoating parameters are shown in Table 1. 
 
Table 1 Process parameters used for enteric-coating and subcoating 
 Eudragit® FS30D Opadry® Opadry® II Opadry® AMB 
Spray rate (g/min) 3 3 3 2 
Atomising pressure (bar) 1.5 2 2 2 
Velocity of air (m/s) 7-8 7-8 7-8 7-8 
Product temperature (°C) 25-30 45 45 45 
 
3.2.2.1. Evaluation of the pellets 
 
Viability of the bacteria after layering, subcoating and enteric coating was determined by the 
Bioscreen turbidity method. For the layered and subcoated pellets 0.1 g pellets were vortexed 
for 30 s in 1 ml sterile water. To evaluate the viability after enteric coating, the bacteria were 
removed from Eudragit® FS30D-coated pellets by stirring 1 g pellets for 1 h in 250 ml 0.0125 
M phosphate buffer pH 7.4 at 37°C. A 0.0125M phosphate buffer was used because a more 
concentrated phosphate buffer had a detrimental effect on the viability of the bacteria. To 
evaluate the viability after gastric passage of the enterically coated pellets, a dissolution test 
during 2 h in 0.1 N HCl was performed using the reciprocating cylinder method (Bio-dis, 
Vankel, NJ, USA) (USP apparatus 3) with 1 g pellets per 250 ml vessel. Afterwards the 
pellets were stirred in 250 ml 0.025 M phosphate buffer pH 7.4 at 37°C on a magnetic stirrer 
until the coating was completely dissolved (visual inspection) and the bacteria released. In 
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this case a non-toxic 0.0125 M phosphate buffer could not be used as it was not able to 
dissolve the enteric coating after 2 h contact with 0.1 N HCl. However, the measured viability 
was corrected for the loss of bacteria due to the toxic effect of a 0.025 M phosphate buffer. 
Some samples were evaluated for viability using the plate count method. Via the pour plate 
method a dilution series of the samples was plated out using GM17T/agar as growth medium 
and after 48 h incubation at 30°C the colony forming units were counted. 
 
3.2.3. Ileum targeting 
 
3.2.3.1. Influence of coating thickness on release profile 
 
3.2.3.1.1. Production of thymidine pellets 
To evaluate the impact of the coating thickness of Eudragit® FS30D on the release profile 
from the pellets, thymidine was incorporated in pellets (1 %) prepared by 
extrusion/spheronisation. Thymidine was selected as marker because of its easier 
quantification than that of L. lactis. Moreover because of its pH-independent release it has 
excellent properties for adequate evaluation of enteric properties of the pellets. Thymidine 
(3.5 g) and microcrystalline cellulose (346.5 g) were preblended and granulated with 350 ml 
demineralised water in a planetary mixer (Kenwood Major Classic, Hampshire, UK). 
Extrusion was performed in a single screw extruder (Dome extruder lab model DG-L1, Fuji 
Paudal, Tokyo, Japan) at 45 rpm, through a 1 mm perforated screen. The extrudate was 
spheronized on a spheronizer (Caleva model 15, Sturminster Newton, UK), using a cross-
hatched friction plate, operating at 1000 rpm with a residence time of 5 min. The pellets were 
dried for 12 h in an oven at 40°C. The 700-1250 μm fraction was separated by sieving.  
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3.2.3.1.2. Enteric coating 
Pellets were enteric coated with Eudragit® FS30D until a polymer weight gain of 5 or 15 % 
was reached. After coating, the pellets were packed in Alu sachets (LPS, Vapor flex barrier 
bag, New Jersey, US) sealed at 20 % RH and stored at -20°C.  
 
3.2.3.1.3. Thymidine release from coated pellets 
Dissolution testing was performed using the reciprocating cylinder method (USP apparatus 3) 
(Bio-Dis, Vankel, NJ, USA) at a dip rate of 21 dpm using 1 g pellets per vessel (250 ml). 
Pellets were consecutively exposed to two media: 0.1 N HCl (2 h) and a 0.05 M phosphate 
buffer at pH 6.8, 7.0 or 7.4 (3 h 40 min). The concentration of thymidine in both dissolution 
media was measured spectrophotometrically (UV-1650PC, Shimadzu, Antwerp, Belgium) at 
267 nm. 
 
3.2.3.2. Chemical modification of Eudragit® FS30D 
 
3.2.3.2.1. Preparation of chemically modified Eudragit® FS30D polymer 
The commercially available Eudragit® FS30D dispersion was added to a water/methanol 
mixture (ratio: 50/50, v/v) in a 25/75 (v/v) ratio of Eudragit® FS30D versus the solvent 
mixture. Different amounts of NaOH (Table 2) were added and the solution was gently mixed 
during 18 h using a magnetic stirrer. After 18 h the polymer was precipitated by adding 0.2 N 
HCl and washed with distilled water. The precipitated polymer was frozen using dry ice in 
aceton, followed by freeze-drying (Lyolab 3000, Heto Lab Equipment, Allerod, Denmark). 
Afterwards the dried polymer was crushed and the powder was sieved to collect the fraction < 
180 μm. 
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Table 2 Different types of chemically modified Eudragit® FS30D 
 Eudragit® FS30D Low level NaOH (LLNaOH) 
Medium level NaOH 
(MLNaOH) 
High level NaOH 
(HLNaOH) 
Amount NaOH 
(mmol/L) 0 94 188 376 
 
3.2.3.2.2. Assessment of the number of methacrylic acid units 
The number of methacrylic acid units was assessed via a colorimetric titration (European 
Pharmacopoeia 6). 5 g polymer (using Eudragit® FS30D as well as the chemically modified 
polymers) was dissolved in isopropyl alcohol/water (ratio: 90/10, v/v). NaOH 0.5 N was used 
as titrant and phenolphthalein as colour indicator. 1 ml of 0.5 N NaOH corresponds with 
43.045 mg methacrylic acid units. 
 
Methacrylic acid units on dry substance (%) =  
x ml 0.5N NaOH × 43.045
 
According to the manufacturer’s specifications, the number of methacrylic acid units of a 
commercially available Eudragit® FS30D dispersion is between 9.2 and 12.3 % (calculated on 
dry substance). 
 
3.2.3.2.3. Evaluation of the ileum-targeting potential of the polymers 
To assess the ileum targeting potential of the polymers (using Eudragit® FS 30D as well as the 
chemically modified polymers) a 10 % polymer solution was prepared in an ethanol/acetone 
mixture (50/50, v/v) and hard gelatin capsules were dip-coated using these polymer solutions. 
The hard gelatin capsules were filled with a lactose/methylene blue mixture, using methylene 
blue as marker for capsule disintegration. Different polymer layers were applied onto the 
capsules by repeatedly dipping them in the polymer solution and drying between each dipping 
step. First, 3 layers were applied on the body of the capsule, followed by 4 layers on the cap 
 ×100 
   Sample weight (mg)  
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and one additional layer on the body. Disintegration of the capsules (indicating dissolution of 
the polymer film) was assessed via an in vitro disintegration test using the apparatus as 
described in the European Pharmacopoeia (PTZ-E Pharma Test, Hainburg, Germany). After 
an initial 2 h in 0.1 N HCl as test medium (37°C, using disks) for disintegration, the capsules 
were transferred to a 0.05 M phosphate buffer (having a pH of 5.5, 6.8, 7.0 or 7.4) to assess 
the ileum-targeting potential based on the capsule disintegration in these buffers. 
 
3.3. Results and discussion 
 
3.3.1. Enteric coating of the layered pellets 
 
MCC pellets were layered for 30 min with L. lactis Thy 12 suspended in a 10 % lactose/20 % 
skim milk suspension (using a 10-fold concentration of L. lactis compared to the overnight 
culture) (see chapter 2 for details) and enterically coated with Eudragit® FS30D. Since enteric 
coating reduced viability (Table 3) with increasing coating thickness, there is a detrimental 
effect of the coating process due to an interaction between L. lactis Thy 12 and the enteric 
coating. This drop in viability could not be linked to a longer exposure time to higher 
temperatures during processing as pellets fluidized for the same time at the coating 
temperature showed no decrease of viability. Moreover, after 2 h in 0.1 N HCl (simulating the 
gastric residence time) viability further decreased; only about 1 % of the bacteria remained 
viable in the coated formulation independent of coating thickness. To avoid direct contact 
between the bacteria and the enteric coat, subcoatings were applied onto the pellets before 
enteric coating. When formulating drugs like omeprazole, subcoatings have been used 
successfully to prevent direct contact between acid-labile drug and the acidic functional 
groups of the enteric coating (Stroyer et al. 2006). In case of Opadry® and Opadry® AMB the 
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viability decreased significantly after subcoating. Only Opadry® II offered protection during 
subcoating. However, when applying an additional enteric coat (5 %) this resulted in an even 
lower viability compared to enteric coating without subcoat (Table 3).  
 
Table 3 Viability (%) (mean ± SD) of L. lactis Thy 12 after layering, subcoating, enteric coating and gastric 
residence 
 After layering Subcoating Enteric coating After 2 h 0.1N HCl 
No subcoating / 
5%: 8.6 ± 2.8 
 
10%: 4.5 ± 1.8 
 
15%: 2.1 ± 0.5 
1.1 ± 0.4 
 
0.6 ± 0.2 
 
0.4 ± 0.4 
Opadry® 3.7 ± 0.5 / / 
Opadry® AMB 3.2 ± 1.8 / / 
Opadry® II 
12.4 ± 1.4 
 
12.5 ± 2.9 5 %: 2.9 ± 1.1 0.9 ± 0.3 
 
A coating thickness of 5 % was selected as a thicker Eudragit® FS30D coat resulted in a 
decrease of viability (Table 3). The viability of pellets after 2 h layering with a concentrated 
bacteria suspension and after coating of these layered pellets with 5 % Eudragit® FS30D was 
13.7 and 7.4 %, respectively. This corresponds to an absolute number (using the plate count 
method) of viable bacteria of 1.7 × 109 ± 1.2 × 108 cfu and 9.9 × 108 ± 8.8 × 107 cfu/100 mg 
pellets, for the layered and coated pellets, respectively. Hence about 10 g pellets is required to 
administer a dose of 1011 cfu. After 2 h in 0.1 N HCl the viability decreased approximately 1 
log unit (1.4 × 108 ± 6.0 × 107 cfu/100 mg).  
As acrylic-based enteric polymers were toxic for the bacterial survival, another enteric 
polymer was evaluated. Sureteric®, a polyvinylacetate-phthalate polymer, was selected 
despite the fact that it already dissolves at pH 5.5 which is too low for ileum targeting. After 
coating viability decreased from 10.5 ± 3.7 % to 3.3 ± 1.7 % and 2.6 ± 1.3 % for a weight 
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gain of 5 and 10 %, respectively. Sureteric® yielded an even lower viability after coating, 
compared to the Eudragit® FS30D polymer (Fig. 2).  
 
0
2
4
6
8
10
12
14
16
18
Sureteric® Eudragit® FS30D
vi
ab
ili
ty
 (%
)
After layering 5% coating 10% coating
 
Figure 2 Viability ± SD (%) after layering and coating with Sureteric® and Eudragit® FS30D 
 
Probably the acidic functional groups, present in both polymers (Fig. 3), are responsible for 
the decrease in viability.  
a  
 
b 
Figure 3 Chemical structure of (a) Eudragit® FS30D and (b) Sureteric® 
84
Enteric protection and ileum targeting of a layered pellet formulation 
3.3.2. Ileum targeting 
  
The release of the IL-10 producing bacteria must be targeted to the ileum, as the ileum is the 
major site of inflammation in patients with Crohn’s disease. Previous results (Huyghebaert et 
al. 2005) showed that the enteric polymers Eudragit® L30D55 and Eudragit® FS30D did not 
result in ileum targeting (i.e. release from pH 6.8): a Eudragit® L30D55 coating (thickness 
corresponding to 30% polymer weight gain) dissolved at a pH lower than 6.8, while a 
Eudragit® FS30D (thickness corresponding to 15 % polymer weight gain) only dissolved at a 
pH above 7.4. An in vivo study showed that HPMC-capsules coated with 15 % Eudragit® 
FS30D resulted in 30 % of the cases in a release distaly from the ileum target site 
(Vanhoutvin et al. 2007).  
A formulation coated with 5 % Eudragit® FS30D, selected based on its low toxicity towards 
L. lactis (Table 3), was evaluated for its ileum targeting capacity, compared to pellets coated 
with 15 % polymer. At pH 6.8 thymidine release (used as marker) was slow with a slightly 
faster release for the 5 % coated pellets (Fig. 4). In phosphate buffer pH 7.0 complete 
thymidine release was obtained after 100 min from pellets coated with 5 % Eudragit®, 
whereas pellets with a 15 % weight gain only released 50 % of the marker after 210 min. The 
influence of coating thickness on release rate was less pronounced at pH 7.4. These results 
indicated that ileum targeting could be improved by reduction of the coating thickness from 
15 to 5 %.  
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Figure 4 Release profiles of thymidine (mean ± S.D., n=3) from pellets coated with 5 (▲) and 15 % (●) 
Eudragit® FS30D after 2 h immersion in HCl 0.1 N and subsequently in buffer solution with pH 6.8 (---, black 
symbols), 7.0 (—, open symbols) and 7.4 (—, black symbols) 
 
In another approach to obtain ileum targeting the commercially available Eudragit® FS30D 
polymer was chemically modified to increase the number of free carboxylic groups. Since the 
dissolution characteristics of anionic copolymers based on methyl acrylate, methyl 
methacrylate and methacrylic acid are determined by the number of free carboxylic groups, 
the objective of the chemical modification of Eudragit® FS30D was to induce release at a 
lower pH. For the Eudragit® FS30D polymer the ratio of free carboxyl groups to ester groups 
is approximately 1:10, for Eudragit® L30D-55 the ratio is 1:1, corresponding to a release 
starting at pH 7.4 and 5.5, respectively. Since release at pH 6.8 is required for ileum targeting, 
neither type of Eudragit® is optimal. Hence it was the objective to increase the number of 
methacrylic acid units of Eudragit® FS30D (via hydrolysis of the ester groups using a strong 
base) to improve its dissolution at lower pH (Fig. 5). Addition of a strong acid after the 
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saponification reaction decreased the aqueous solubility of the polymer and the chemically 
modified polymer can be collected and washed.  
 
 
Figure 5 Hydrolysis or saponification of a carboxylate ester 
 
Different amounts of NaOH were added to Eudragit® FS30D resulting in 3 grades of modified 
polymer, characterised by a different number of free carboxylic groups (Fig. 6). The 
unmodified polymer had 10.0 % methacrylic acid units (on polymer dry weight) 
(corresponding with the specification of the manufacturer) and the free carboxylic groups 
increased in function of the NaOH concentration during chemical modification: 12.2, 21.8 
and 39.0 % using 94, 188, 276 mM NaOH, respectively. Based on the fraction of free COOH-
groups these chemically modified polymers are potential candidates for ileal targeting since 
the percentage of methacrylic acid groups is between the values for Eudragit® L30D55 (46.0-
50.6 %, having a too fast release) and Eudragit® FS30D (9.2-12.3 %, having a too slow 
release). 
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Figure 6 Percentage of methacrylic acid units (on polymer dry weight) in unmodified and modified Eudragit® 
FS30D polymers. Eudragit® FS30D was chemically modified using different NaOH concentrations for 
saponification of the ester groups: 94, 188 and 276 mM for LLNaOH, MLNaOH and HLNaOH, respectively. 
 
Capsules filled with methylene blue as marker were dip-coated with these polymers dissolved 
in organic solvents and its enteric properties (ability to withstand 2 h in 0.1N HCl) as well as 
the pH required for disintegration were assessed. To obtain ileum targeting the capsule should 
remain intact below pH 6.8 and disintegrate at pH 6.8 within 60 min. The disintegration 
properties of the coated capsules are summarized in Table 4. All coated capsules had 
sufficient enteric properties as no disintegration occurred within 2 h in 0.1 N HCl. As 
expected the capsules coated with unmodified polymer (Eudragit® FS30D) only disintegrated 
at pH 7.4. When the polymer chemically modified with the lowest concentration of NaOH 
(LLNaOH) was used no disintegration occurred at pH 6.8, however the capsules opened after 20 
min at pH 7.0. Using an intermediate NaOH concentration (MLNaOH) the capsule opened after 
20 min in pH 5.5. As the MLNaOH polymer already released its content at a pH too low for 
ileum targeting, the polymer chemically modified with the highest NaOH concentration 
(HLNaOH, containing the highest fraction of free carboxylic groups) was not tested.  
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Table 4 Disintegration times ± SD (min) of capsules (n=3) coated with Eudragit® FS30D and polymers modified 
using different concentrations of NaOH (LLNaOH and MLNaOH)  
 Eudragit® FS30D LLNaOH MLNaOH 
0.1N HCl No disintegration (2h) No disintegration (2h) No disintegration (2h) 
pH 5.5 No disintegration (1h) No disintegration (1h) 20 ± 4 min 
pH 6.8 No disintegration (1h) No disintegration (1h) - 
pH 7.0 No disintegration (1h) 20 ± 2 min - 
pH 7.4 55 ± 5 min - - 
- : not tested 
 
3.4. Conclusion 
 
Layered pellets were protected by Eudragit® FS30D against the gastric fluid, resulting in an 
acceptable cell load of 1.4 × 108 cfu/100 mg after gastric passage. The enteric polymer itself 
and small amounts of acid that penetrated in the layer of bacteria decreased the bacterial 
survival. Ileum targeting could be achieved with a thin coat of Eudragit® FS30D, resulting in 
release at pH 7.0, close to the ileum pH of 6.8. Modification of Eudragit® FS30D by 
increasing the number of free carboxylic groups, resulted in a polymer suitable for ileum 
targeting. 
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IN VIVO EVALUATION OF THE VAGINAL 
DISTRIBUTION AND RETENTION OF A MULTI-
PARTICULATE PELLET FORMULATION 
 
4.1. Introduction 
 
To deliver probiotic bacteria to the vaginal region, layered pellets were proposed as delivery 
system. However, pellets have not yet been used as vaginal delivery system, hence their 
behaviour after vaginal administration should be evaluated. The application of pellets for 
vaginal delivery is not limited to probiotics, but can be extended to microbicides against HIV 
infection (Garg et al. 2003), to antifungal and antimicrobial drugs for local drug action or to 
large molecular weight drugs like peptides and proteins (Richardson and Illum 1992) for 
systemic drug delivery. An optimal vaginal formulation should have (1) a long retention time 
to maximise drug release, and (2) a proper spreading over the vaginal epithelium to obtain fast 
absorption or to maximize the effect in case of local treatment, should (3) be easy to 
administer and (4) not cause discomfort to improve patient compliance. Most of the vaginal 
formulations are cleared too fast from the vaginal cavity as a result of the self cleansing action 
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of the vagina and/or because the vaginal formulation failed to attain a proper distribution over 
the vaginal mucosa (Woolfson et al. 2000). Pellets are herewith proposed as a novel vaginal 
drug delivery system as it is anticipated that due to their small particle size they will evenly 
distribute over the vaginal epithelium and will be less sensitive to gravity, resulting in a 
longer retention time. The in vivo behaviour (vaginal distribution and retention) and patient 
acceptability (irritation, discomfort) of non-disintegrating microcrystalline cellulose (MCC) 
and disintegrating starch-based pellets were evaluated following administration of these 
pellets packed in hydroxypropylmethylcellulose (HPMC) or hard gelatin capsules. The 
vaginal distribution and retention of a freeze-dried powder (lactose/skim milk) packed in a 
capsule was also evaluated. In addition the influence of the carrier material on the vaginal pH 
and microflora was verified. 
 
4.2. Materials and methods 
 
4.2.1. Materials 
 
Microcrystalline cellulose (MCC) (Cellets® 500 μm, Pharmatrans-Sanaq, Basel, Switzerland) 
were used as non-disintegrating pellets. Disintegrating starch-based pellets were prepared via 
extrusion/spheronisation using a high amylose, crystalline and resistant starch (Uni-Pure®EX 
starch, National Starch and Chemical Company, New Jersey, USA) as main excipient 
(concentration 84.9 %). Hydroxypropylmethylcellulose (HPMC) (Methocel® E15 LV EP 
Pharm, Colorcon, Dartford, UK) (4.9 %) was used as a binder in the pellets and sorbitol 
(Sorbidex® P 16616, Cerestar, Vilvoorde, Belgium) (10.2 %) was added to modify the 
consistency of the wet mass (Dukic et al. 2007). Demineralised water was used as granulation 
liquid. Riboflavin sodium phosphate (Certa, Braine l’Alleud, Belgium) (concentration: 5 %) 
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was added as a marker to visualise the spreading and to quantify the retention time of the 
formulation in the vaginal cavity. 
 
4.2.2. Preparation of the pellets 
 
Starch-based pellets were produced by extrusion/spheronisation. Dry mixing was performed 
in a Turbula® mixer (model T2A, W.A. Bachofen, Basel, Switzerland) for 15 min. The 
powder mixture was granulated with demineralised water for 10 min using a planetary mixer 
(Kenwood Chief, Hampshire, UK) with a K-shaped mixing arm. Water was added during the 
first 30 s of the wet massing phase. To ensure uniform water distribution, the material 
adhering to the mixing bowl was regularly removed. The wet mass was extruded at an 
extrusion speed of 50 rpm using a single screw extruder (Dome extruder lab model DG-L1, 
Fuji Paudal, Tokyo, Japan) equipped with a dome-shaped extrusion screen with 0.4 mm 
perforations. The extrudates were spheronised in a spheroniser having a friction plate with 
cross-hatched geometry (Caleva Model 15, Caleva, Sturminster Newton, Dorset, UK). 
Spheronisation time was 3 min and spheronisation speed 1000 rpm. The pellets were 
overnight dried in an oven (Memmert, Schwabach, Germany) at 40°C. The size fraction of 
315 - 800 μm was separated using a sieve shaker (Retsch, Haan, Germany). Pellets were 
packed into HPMC (size 00, Vcaps, Capsugel, Bornem, Belgium) or gelatin (size 00, 
Intercaps, Aca pharma, Waregem, Belgium) capsules. The number of pellets per capsule was 
about 7500. 
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4.2.3. Preparation of the freeze-dried powder 
 
An aqueous dispersion of 10 % lactose (α-Pharma, Braine-l’Alleud, Belgium) and 20 % skim 
milk (Difco, Becton Dickinson, MA, USA) was freeze-dried using an Amsco Finn Aqua GT4 
freeze-dryer (Amsco, Germany). The dispersion was frozen to -45°C within 175 min at 
1000 mbar. Primary drying was performed at -15°C and at a pressure varying between 0.8 and 
1 mbar during 13 h, followed by secondary drying at elevated temperature (10°C) and 
reduced pressure (0.1–0.2 mbar) for 7 h. The powder was packed into HPMC or hard gelatin 
capsules (size 00). 
 
4.2.4. In vitro disintegration of pellets and capsules 
 
Simulated vaginal fluid (Owen and Katz 1999) was used as test medium to evaluate the 
disintegration properties of the pellets using the watch glass method to simulate vaginal 
disintegration (Yamaguchi et al. 1990a; Yamaguchi et al. 1990b). One g of pellets was placed 
on the centre of a watch glass (diameter of 11 cm), which floated on a water bath at 37°C. 4 
ml simulated vaginal fluid (37°C) was poured on the pellets and disintegration was evaluated 
by touching the pellets with dumb and index finger at regular time points. The disintegration 
time was defined as the time point at which the pellets consisted of a soft mass with no 
palpably firm, unmoistened core. The disintegration time of HPMC and hard gelatin capsules 
was assessed using the same procedure, the disintegration time was defined as the time point 
at which the pellets were released from the capsules. 
 
 
 
94
In vivo evaluation of the vaginal distribution and retention of a multi-particulate pellet formulation 
4.2.5. In vivo tests 
 
4.2.5.1. Evaluation of vaginal distribution and retention of pellet and powder 
formulations 
 
Clinical trials were performed with healthy volunteers (5 volunteers in each group). 
Volunteering women were screened to exclude gynaecological and systemic pathology, 
including cervico-vaginal infections or vaginal microflora alterations according to a 
standardized protocol. Only nullipara healthy premenopausal volunteers aged between 18 and 
50 year were included in the study. Study participants adhered to a strict protocol that 
involved an extensive list of behaviours they were to refrain from to avoid interference with 
the vaginal formulation, including abstinence from coitus for 48 hours prior to and 24 h after 
administration of the product, no use of vaginal hygiene products (spray, foams,…) and no 
depilation of pubic hair. To avoid interference with menstrual or withdrawal bleeding, study 
participants adhered to a continuous oral contraceptive regimen during the conduct of the 
studies. All in vivo experiments were approved by the ethical committee of Ghent University 
Hospital. 
Two pellet and one powder formulation were administered: non-disintegrating MCC pellets, 
fast-disintegrating starch-based pellets and a freeze-dried lactose/skim milk powder 
(containing 5 % riboflavin sodium phosphate as marker). These products were administered 
using HPMC or hard gelatin capsules. Capsules were administered high in the vagina at the 
fornix posterior using a commercially available applicator (Infemin applicator, Pierre Fabre 
santé Benelux, Brussels, Belgium). All volunteers remained supine for 3 or 6 h after 
administration of the formulation and underwent colposcopy after 3, 6 or 24 h. The in vivo 
behaviour of capsules and pellets (disintegration and spreading) was assessed via colposcopy 
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using photographs (n=12) to monitor the entire ectocervical and vaginal mucosa. Table 1 
details the formulations administered to each group of volunteers (n=5) and the time points at 
which colposcopy was performed. 
 
Table 1 Overview of the study groups used to evaluate the in vivo behaviour (disintegration, spreading, retention 
time) of pellets and capsules after vaginal administration 
Group Formulation Capsule type Colposcopy RSP* marker 
1 Microcrystalline cellulose pellets HPMC 3 h and 24 h - 
2 Starch-based pellets HPMC 6 h and 24 h + 
3 Starch-based pellets HPMC 24 h + 
4 Freeze-dried powder HPMC 6 h and 24 h + 
5 Starch-based pellets Gelatin 6 h and 24 h + 
* RSP: riboflavin sodium phosphate 
 
Using pellets or powder with riboflavin sodium phosphate (RSP) as marker, the vaginal 
discharge of pellets and powders was monitored over a period of 24 h using panty shields. 
After 6, 12 and 24 h the panty shields were replaced and the RSP amount on each panty shield 
was determined. To monitor the vaginal distribution of the formulation, the fornix, the mid 
portion of the vault mucosa and the introitus were swabbed during colposcopy and the 
fraction of RSP detected at the different sites was assessed. 
 
4.2.5.1.1. Analysis of the panty shields and swabs 
To determine the amount of riboflavin sodium phosphate, the panty shields and swabs were 
stirred for 24 h protected from light in 500 and 5 ml demineralised water, respectively. The 
RSP concentration in a filtered (Spartan 30/0.2 RC membrane filter, Whatman, Schleicher & 
Schuell, Dassel, Germany) sample was measured spectrophotometrically at 266 nm (UV-
96
In vivo evaluation of the vaginal distribution and retention of a multi-particulate pellet formulation 
1650PC, Shimadzu, Antwerp, Belgium). The amount of RSP recovered was expressed as the 
percentage of the total administered RSP dose.  
 
4.2.5.2. Evaluation of the vaginal pH and microflora after administration of 
starch-based pellets and lactose/skim milk powder 
 
To evaluate the effect of the excipients used as carrier material in the vaginal formulations a 
double-blind, randomised, parallel study was performed with 24 healthy volunteers: 2 groups 
of each 8 women followed a 5-day treatment with hard gelatin capsules filled with (a) starch-
based pellets and (b) freeze-dried lactose/skim milk powder, whereas no formulation was 
vaginally administered in the control group (n=8) (i.e. no treatment). The same inclusion and 
exclusion criteria were used as during evaluation of the vaginal retention time and spreading. 
In addition no local or systemic antibiotics (including anti-mycotics and anti-protozoics) were 
allowed during a period of 3 weeks before the start of the study and only volunteers with 
normal microflora were included. The latter was assessed via vaginal swabbing and analysis 
of the vaginal microflora. 
During the 5-day treatment period one capsule per day was self-administered by the 
volunteers just before bedtime using a vaginal applicator. On day 14 the intake of the 
monophasic pill was stopped to cause menstruation. 
On day 6 (1 day after administration), 14, 22 (after menstruation) and 35 the volunteer 
underwent a gynaecological examination. Vaginal pH was measured using a pH test strip 
(Macherey-Nagel GmbH, Düren, Germany) and the vagina was swabbed with an ESwab 
(Copan diagnostics, Corona, CA, USA). Swabs were used for Gram-staining and culturing to 
identify H2O2-producing strains at the Laboratory for Bacteriological Research (Ghent 
University Hospital). 
97
Chapter 4 
4.2.5.2.1. Gram-staining 
Swabs were smeared on a plane glass slide and air-dried at room temperature. The slides were 
Gram-stained, examined under oil immersion at a magnification of 1000 (Mirastainer, Merck-
Belgolab, Overijse, Belgium) and assigned a score according to Verhelst et al. (2005). 
Accordingly, Gram-stained vaginal smears were categorized: 
- grade Ia: only Lactobacillus crispatus cell types  
-  grade Ib: only other Lactobacillus cell types  
- grade Iab: both L. crispatus and other lactobacilli  
-  grade I-like: Gram positive rods  
-  grade II (intermediate): Lactobacillus and Gardnerella or Bacteroides-Prevotella cell 
types 
-  grade III (bacterial vaginosis): no Lactobacillus cell types, only Gardnerella, 
Bacteroides-Prevotella or Mobiluncus cell types  
-  grade IV: predominantly Gram positive cocci 
 
4.2.5.2.2. Evaluation of H2O2-production 
Swabs were smeared on a TMB plus agar plate (Rabe and Hillier 2003) and incubated for 2 
days at 37°C in an anaerobic chamber (BugBox, Ruskinn Technology, LedTechno, Heusden-
Zolder, Belgium). The TMB plus agar plate was exposed to air after incubation to evaluate 
the amount of H2O2-production. H2O2-production appeared as a blue colour and the number 
of H2O2-producing colonies and the colour intensity was used to score the H2O2-production 
(0: no H2O2-production, 1: poor H2O2-production, 2: strong H2O2-production and 3: very 
strong H2O2-production). 
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4.3. Results and discussion 
 
4.3.1. In vivo and in vitro evaluation of the distribution and retention of different 
pellet and powder formulations 
 
Pellets, packed in HPMC or hard gelatin capsules, were evaluated as a new vaginal drug 
delivery system. The capsule disintegration time, spreading and retention of the different 
pellet formulations (non-disintegrating MCC pellets versus disintegrating starch-based 
pellets) and patient acceptability of this dosage form for vaginal application were assessed.  
HPMC capsules filled with pellets (MCC or starch-based pellets) adhered well to the vaginal 
mucosa as no capsules were lost (Groups 1-3, n=15). Although HPMC capsules disintegrated 
in vitro within 10 minutes, in vivo disintegration was much slower as even after 6 h 3 out of 5 
capsules (Group 2) were still intact. The lack of correlation between in vitro and in vivo 
results was probably due to the very low amount of vaginal fluid. However, the capsule wall 
was weakened as even the slightest touch with the speculum during colposcopy opened the 
wetted capsules. 24 h after administration all capsules had opened and no capsule remnants 
were detected. In case of powder-filled HPMC capsules, all capsules (Group 4, n=5) had 
disintegrated 6 h after administration. Although in vitro disintegration was faster for hard 
gelatin capsules compared to HPMC capsules (3 versus 10 min), their in vivo behaviour was 
similar to that of HPMC capsules as 2 out of 5 (Group 5) were still intact 6 h after 
administration. This slow capsule disintegration would affect the drug release rate, but this 
disadvantage could be eliminated if the pellets were administered in the vaginal cavity using 
an applicator with a different design which does not require that the pellets are packed in a 
capsule. 
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In those volunteers where the HPMC capsule (filled with non-disintegrating MCC pellets) 
(Group 1) had already disintegrated 3 h after administration, pellets clustered around the 
fornix and no spreading over the lateral walls to the introitus occurred (Fig. 1a). After 24 h a 
limited number of pellets (< 50) were located at the midportion of the vagina and around the 
introitus (Fig. 1b) as the volunteers reported that the majority of the pellets was discharged 
between 5-7 h after administration, mainly during toilet visit and showering. Chatterton et al. 
(2004) also reported the most loss of a vaginal cream formulation during urination. Hence, 
despite their small particle size and spherical shape, pellets did not spread evenly and vaginal 
retention was limited for MCC pellets.  
 
a       b 
   
Figure 1 Right side of fornix 3 h (a) and left side of the mid vagina 24 h (b) after administration of an HPMC 
capsule, filled with non-disintegrating MCC pellets 
 
Although starch-based pellets also clustered around the fornix 6 h after administration, the 
pellets already started to disintegrate and spreading of the pellets was observed (Fig. 2a) 
(Group 2). After 24 h for 8 out of 10 volunteers (Group 2-3) complete coverage of the vaginal 
mucosa with disintegrating pellets was observed (Fig. 2b) as visualised via RSP as a marker.  
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a      b 
  
Figure 2 The fornix anterior 6 h (a) and anterior side of the mid vagina 24 h (b) after administration of an 
HPMC capsule, filled with disintegrating starch-based pellets  
 
Vaginal swabbing showed that after 6 h, RSP was almost only detected around the fornix, but 
after 24 h RSP was recovered from all swabbed areas, although the highest concentration was 
still detected around the fornix (Table 2). In relation to the total amount of RSP administered, 
the amount recovered via swabbing was low, partly because a fraction of the RSP was already 
discharged from the vagina, but mainly because only a limited area of the vaginal mucosa was 
swabbed. In several volunteers no RSP was detected on the swabs taken after 6 h as in these 
patients the capsules had not yet opened. 
 
 
 
 
 
 
 
101
Chapter 4 
Table 2 % RSP of the administered dose detected by swabbing at the fornix, mid vagina and introitus 6 and 24 h 
after vaginal delivery of an HPMC capsule filled with starch-based pellets (Group 2) or freeze-dried powder 
(Group 4), with RSP as marker substance 
  6 h    24 h   
 Fornix Mid vagina Introitus Total Fornix 
Mid 
vagina Introitus Total 
 Starch-based pellets 
Volunteer 1 0.14 0.01 0.00 0.15 0.70 0.25 0.04 0.99 
Volunteer 2 - - - - 0.49 0.10 0.10 0.69 
Volunteer 3 0.60 0.00 0.00 0.60 0.15 0.02 0.00 0.17 
Volunteer 4 - - - - 0.14 0.01 0.00 0.15 
Volunteer 5 0.48 0.02 0.00 0.50 0.34 0.13 0.02 0.49 
Mean 0.41 0.01 0.00 0.25 0.37 0.10 0.03 0.50 
 Freeze-dried powder 
Volunteer 1 0.30 0.05 0.00 0.35 0.07 0.01 0.00 0.08 
Volunteer 2 0.04 0.00 0.00 0.04 0.00 0.00 0.00 0.00 
Volunteer 3 0.47 0.15 0.17 0.79 0.05 0.02 0.00 0.07 
Volunteer 4 0.01 0.04 0.02 0.07 0.03 0.03 0.00 0.06 
Volunteer 5 0.82 0.00 0.00 0.82 0.29 0.08 0.00 0.37 
Mean 0.33 0.05 0.04 0.41 0.09 0.03 0.00 0.12 
- : capsule still intact 6 h after vaginal administration 
 
After 6 h the powder formulation was mainly spread around the fornix, but already some 
distribution to the middle anterior and posterior wall of the mid vagina was observed (Table 
2) (Fig. 3a) (Group 4). No coverage of the side walls of the vagina midportion was seen. In 
one volunteer the powder had formed a plug and no spreading occurred. Colposcopy after 24 
h revealed only a small amount of powder (n=5) at the posterior and anterior vaginal walls 
(Fig. 3b), indicating that the powder was faster cleared from the vagina in comparison to 
pellets. After dispersion of the powder it behaved like liquid and was rapidly cleared from the 
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vagina. In one volunteer, no powder was detected, whereas another volunteer showed 
complete vaginal coverage after 24 h.  
 
a      b 
  
Figure 3 The anterior side of the mid vagina 6 h (a) and right side of the mid vagina 24 h (b) after administration 
of an HPMC capsule, filled with powder  
 
To evaluate the vaginal clearance of starch-based pellets compared to the powder formulation, 
pellets and powder discharged from the vagina were collected on panty shields. However, 
since most pellets and powder were lost during toilet visit and showering, these data did not 
provide meaningful information.  
 
During the clinical trials only minor side effects were reported by the volunteers (Groups 1-5, 
n=25): an irritated feeling by one woman and minor low belly pain shortly after 
administration of the capsule by 3 volunteers. As there was no control group and none of the 
side effects were severe, they could not be conclusively associated with product use. 
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4.3.2. In vivo evaluation of the vaginal pH and vaginal flora after pellet and 
powder administration 
 
If starch-based pellets or lactose/skim milk powder are used as carrier for vaginal probiotic 
bacteria, it is important to assess the influence of the carrier itself on the vaginal pH and 
microflora. A control group was included to follow the natural evolution of pH and microflora 
during a menstrual cycle. Table 3 and Figure 4 shows the average vaginal pH and H2O2-
scores and Table 4 shows the Gram-staining results in the three groups (control, pellets and 
powder) at screening, day 6 (one day after the 5-day administration period), day 14, day 22 
(after menstruation) and day 35. Only volunteers with normal microflora were included in the 
study. pH at screening was for all but two volunteers lower than 4.7, which is considered as a 
normal vaginal pH (range 3.5-4.7). At day 6 (just after administration) and day 14, pH and 
microflora were normal for all groups. At day 22, just after menstruation, mean pH increased 
in all groups, however this was due to the period in the menstrual cycle (presence of 
menstrual flow) and not due to treatment. At day 35 only one person showed a vaginal pH 
above 4.7.  
 
Table 3 pH and H2O2-score (mean ± SD) in control, starch-based pellets and freeze-dried powder group 
 Screening Day 6 Day 14 Day 22 Day 35 
 pH 
Control group 4.3 ± 0.9 3.8 ± 0.3 3.7 ± 0.2 4.8 ± 1.4 4.0 ± 0.2 
Starch-based 
pellets 4.5 ± 0.9 4.3 ± 0.5 3.9 ± 0.3 5.0 ± 0.8 4.1 ± 0.3 
Freeze-dried 
powder 4.0 ± 0.4 3.8 ± 0.3 3.7 ± 0.2 4.5 ± 0.8 4.3 ± 0.6 
 H2O2-score 
Control group 2.0 ± 1.3 2.3 ± 1.2 2.3 ± 1.2 0.8 ± 0.8 1.7 ± 1.0 
Starch-based 
pellets 2.0 ± 0.6 2.0 ± 0.9 2.5 ± 0.8 1.3 ± 0.8 1.8 ± 0.4 
Freeze-dried 
powder 1.7 ± 1.0 2.0 ± 1.1 1.7 ± 0.8 0.7 ± 0.5 1.5 ± 0.8 
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Figure 4 Mean pH (—) and H2O2-score (---) in control (■), starch-based pellets (▲) and freeze-dried powder (○) 
group 
 
Just after menstruation (day 22) 5 abnormal microflora was detected (Table 4), however, 
again this phenomenon was only due to menstrual bleeding and was not related to treatment 
(Keane et al. 1997, Eschenbach et al. 2000). Moreover, 3 of the 5 abnormal microfloras were 
detected in the control group. At day 35, 2 abnormal microflora was detected in the pellet 
group, however as this abnormal microflora only appears at day 22 and day 35, it was 
concluded that this change in microflora was not caused by the administered pellet 
formulation. H2O2-production scores of the vaginal microflora at screening were comparable 
with the production scores on day 35 (Table 3, Fig. 4). On day 22 there was a decrease in 
H2O2-scores in all groups, indicating that just after menstruation there is a decrease in H2O2-
producing strains (Keane et al. 1997, Eschenbach et al. 2000). H2O2-producing vaginal strains 
are important for a healthy vaginal microflora as the produced H2O2 is bactericidal for 
bacterial vaginosis associated microorganisms. 
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Microflora and pH at screening and day 35 were similar for all study groups, indicating that 
starch-based pellets and freeze-dried lactose/skim milk are acceptable carrier materials for the 
vaginal delivery of probiotic bacteria or other drugs. 
 
Table 4 Gram-staining results in control, starch-based pellets and freeze-dried powder group 
 Screening Day 6 Day 14 Day 22 Day 35 
 Control group 
Volunteer 1 Ia Ia Ia Ia Ia 
Volunteer 2 Ia Ia Ia Ia Ia 
Volunteer 3 Ia Ia Ia Ia Ia 
Volunteer 4 Ib Ia Ia II Ia 
Volunteer 5 Iab Ib Ia or b III Ia or b 
Volunteer 6 Ia Ia Ia II Ia 
 Starch-based pellets 
Volunteer 1 Ib Ib Ib/I-like I-like I-like 
Volunteer 2 Ia Ia Ia Iab Ia 
Volunteer 3 Ib Ib Ib Ib Ib 
Volunteer 4 Ia Ia Ia / Ia 
Volunteer 5 Ia Ia Ia Iab Ia(b) 
Volunteer 6 Ib Ib Ib Ib III 
 Freeze-dried powder 
Volunteer 1 Ib Ib Iab Iab Ia(b) 
Volunteer 2 Ib Ib Ib + a Ia Ib 
Volunteer 3 Ia Ia Ia Ia Ia 
Volunteer 4 Ia Ia Ia Ia Ia 
Volunteer 5 Ia Ia Iab Ia Ia 
Volunteer 6 Ia Ia Ia Ib Iab 
Red: abnormal microflora 
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4.4. Conclusion 
 
Disintegrating starch-based pellets have been identified as a promising novel vaginal drug 
delivery system, which resulted in complete coverage of the vaginal epithelium. A drawback 
of this formulation was the slow disintegration of the capsules, however using an applicator 
that does not require to pack the pellets in capsules prior to vaginal delivery would eliminate 
this problem. These starch-based pellets are acceptable carriers for probiotic bacteria or other 
drugs, as the carrier itself had no influence on vaginal pH and microflora. 
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DEVELOPMENT OF A VAGINAL 
FORMULATION OF LACTOBACILLUS SPECIES 
AND IN VIVO EVALUATION IN HEALTHY 
VOLUNTEERS 
 
5.1. Introduction 
 
Bacterial vaginosis and yeast vaginitis are affecting a large number of women and these 
ailments are major public health concerns. Generally within these patients the normal vaginal 
microflora is disturbed and the natural protection against infectious microorganisms is lost. 
The use of probiotic microorganisms to restore the normal vaginal flora is gaining interest as 
an alternative to conventional antibiotic treatment (Andreu 2004; Falagas et al. 2007; 
Famularo et al. 2001; Hoesl and Altwein 2005; Reid and Bruce 2003). Four vaginal strains 
have been identified at the Laboratory for Bacteriology Research (Ghent University Hospital) 
(Saerens 2006) as potential probiotics to treat bacterial vaginosis, i.e. Lactobacillus jensenii 
PB204-T1-1, Lactobacillus crispatus PB125-T1-1, Lactobacillus crispatus PB128-T1-1 and 
Lactobacillus gasseri PB088-T2-1. These strains were selected based on their (1) capacity to 
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produce H2O2, (2) inhibition of Gardnerella vaginalis, Atopobium vaginae and uropathogenic 
Escherichia coli, (3) absence of bacteriophage production, (4) absence of growth inhibition of 
other Lactobacillus species.  
However, to efficiently deliver these probiotics to the vagina these strains must be formulated 
in a dosage form that maintains the viability of these microorganisms during manufacturing 
and shelf life. In addition the carrier formulation of the probiotics must ensure that residence 
time and spreading of viable microorganisms in the vaginal cavity is sufficient to colonize the 
vagina and restore the microflora. Therefore this study evaluates the viability of the selected 
lactobacilli strains in function of the manufacturing technique (freeze-drying versus layering 
on inert carriers) using different dosage forms (layered pellets, powder) and excipients 
(lactose, skim milk, trehalose, vitamin C) to maximize viability. The benefits of tangential 
flow filtration compared to centrifugation for harvesting the bacteria from the culture medium 
were also evaluated. Finally a clinical trial in healthy volunteers was performed to compare 
the vaginal colonisation potential of 3 probiotic strains, administered via layered pellets or 
freeze-dried powder. 
 
5.2. Materials and methods 
 
5.2.1. Materials 
 
Growth medium MRS was purchased from Oxoid (Cambridge, UK). Tryptic Soy Agar (TSA) 
plates, enriched with 5 % sheep blood, were obtained from Becton Dickinson (Becton 
Dickinson, Franklin Lakes, NJ, USA). Microcrystalline cellulose pellets were used as inert 
carriers for the layering experiments (Cellets® 500 μm, Pharmatrans-Sanaq, Basel, 
Switserland). Lactose (α-Pharma, Braine-l’Alleud, Belgium), skim milk (Difco, Becton 
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Dickinson, MA, USA), trehalose (Cerestar, Mechelen, Belgium) and vitamin C (Certa, 
Braine-l’Alleud, Belgium) were used as stabilisers. During the in vivo study starch-based 
pellets consisting of  7.0 % hydroxypropylmethylcellulose (Methocel® E15 Colorcon, 
Dartford, UK), 10.1 % sorbitol (Cerestar, Mechelen, Belgium) and 82.9 % starch (Uni-
Pure®EX starch, National Starch and Chemical Company, New Jersey, USA) were used as 
carriers for the lactobacilli. 
 
5.2.2. Bacterial strains 
 
Lactobacillus jensenii PB2003/204-T1-1, Lactobacillus gasseri PB2003/088-T2-1, 
Lactobacillus crispatus PB2003/125-T1-1 and Lactobacillus crispatus PB2003/128-T1-1 
were obtained from the Laboratory for Bacteriology Research (Ghent University Hospital). A 
stock of each individual Lactobacillus strain was stored at -70°C in TSB (Tryptic Soy Broth) 
with 15 % glycerol. 
 
5.2.3. Preparation of the layering and freeze-drying suspensions 
 
Bacteria were inoculated from the stock solution on a TSA plate enriched with 5 % sheep 
blood and incubated for 48 h at 37°C under anaerobic conditions (BugBox, Ruskinn 
Technology, LedTechno, Heusden-Zolder, Belgium). After 48 h one colony was isolated and 
inoculated in 5 ml MRS broth under anaerobic conditions for 24 h (overnight culture), where 
after a preculture of 100 ml was inoculated with 1 ml of the overnight culture and incubated 
for another 24 h. 10 L of Lactobacillus culture was prepared by inoculating 10 flasks with 1 L 
MRS broth with 10 ml of the preculture. The 10 L cultures were grown until the stationary 
phase was reached, i.e. 17 h for L. jensenii, 48 h for L. gasseri and L. crispatus 128 and 72 h 
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for L. crispatus 125. For L. crispatus 125 an MRS-acetate broth (pH 6) was used. In one 
experiment the growth medium was enriched with 6 g/L trehalose as additional carbon source. 
Afterwards the bacteria were collected by centrifugation (Beckmann JA10 rotor, Munchen, 
Germany). The centrifugation parameters are summarised in Table 1. 
 
Table 1 Centrifugation parameters used to harvest the bacteria from the growth medium 
 g Time (min) Temperature (°C) 
L. jensenii 2800 15 4 
L. gasseri 3100 20 4 
L. crispatus 125 2800 20 4 
L. crispatus 128 3100 20 4 
 
To obtain a 100-fold concentrated bacterial suspension the cell pellet harvested from a 10 L 
culture was resuspended in 100 ml of a 10 % lactose/20 % skim milk (w/v) solution which 
was used as stabilising matrix to maintain the viability of the lactobacilli strains during 
processing. To prevent further activity or growth, the cultures were kept on ice during all 
handling steps. In additional experiments 1 % vitamin C was added to the stabilising matrix or 
the lactose fraction was substituted by trehalose. 
In addition a 50 L culture of L. crispatus 128 was grown using a U50 Bioreactor (Sartorius 
BBI systems, Goettingen, Germany) at the Laboratory of Industrial Microbiology and 
Biocatalysis (Faculty of Bioscience Engineering, Ghent University). A pre-culture of 5 ml 
MRS broth was inoculated in 500 ml MRS broth. After 26.5 h at 37°C a mid-exponential 
culture was obtained and inoculated in the 50 L fermentor. Fermentation was performed at a 
rotational speed of 150 rpm without aeration and after 25 h the stationary phase was reached. 
After 40 h the culture was centrifuged (Cepa-centrifuge, Lahr, Germany) for 45 min at a 
rotation speed of 17670g.  
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5.2.4. Layering process 
 
As the inert carrier had no influence on the viability of Lactococcus lactis after layering (see 
Chapter 2), MCC pellets (Cellets® 500 μm) were used as inert carriers to assess the viability 
of the lactobacilli. Layering was performed using the protocol described in Chapter 2. After 
layering pellets were packed in Alu sachets (LPS, Vapor flex barrier bag, NJ, US) and stored 
for up to 1 year at -20 and 4°C and at 20 % relative humidity. 
 
5.2.5. Freeze-drying 
 
Petri dishes (diameter: 85 mm) filled with 20 ml of the bacterial suspension were freeze-dried 
using an Amsco Finn Aqua GT4 freeze-dryer (Amsco, Germany). The dispersion was frozen 
to -45°C within 175 min at 1000 mbar. Primary drying was performed at -15°C and at a 
pressure varying between 0.8 and 1 mbar during 13 h and was followed by secondary drying 
at elevated temperature (10°C) and reduced pressure (0.1–0.2 mbar) for 7 h. The obtained 
cake was crushed with mortar and pestle, packed in Alu sachets and stored for up to 1 year at 
-20 or 4°C and a relative humidity of 20 %. 
 
5.2.6. Harvesting of bacteria by tangential flow filtration 
 
Tangential flow filtration was performed by means of a Proflux M12 system (Millipore, 
Bellerica, MA, USA) using a 0.45 μm polyvinylidene fluoride membrane (Durapore V-screen 
Pellicon 2 cassettes) to isolate the microorganisms (Fig. 1). 2 L stationary phase cultures were 
prepared of the four Lactobacillus strains. The culture was separately added to the reservoir 
compartment and concentrated with a permeate flow of about 115 ml/min until the minimum 
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working volume of the M12 Proflux system was reached (about 110 ml). The retentate was 
collected and the filter unit flushed with 200 ml fresh MRS to collect the bacteria retained on 
the membrane. The concentrated culture and the MRS flush medium were centrifuged at 
3000g for 20 min to remove the residual growth medium. The cell pellet was resuspended in 
20 ml stabilising matrix (10 % lactose/20 % skim milk, w/v) and freeze-dried as described 
above. To compare the different techniques used to harvest lactobacilli from the growth 
medium (centrifugation vs. tangential flow filtration) a 2 L stationary phase culture was 
simultaneously processed by centrifugation and the resulting cell pellet was also freeze-dried 
after resuspending in 20 ml stabilising matrix. Viability of the microorganisms in the 
stationary phase culture, the MRS flush, the stabilising matrix and the freeze-dried powder 
was assessed. 
 
 
Figure 1  The proflux M12 system 
 
 
 
 
 
Reservoir compartment 
Durapore 0.45 μm membrane 
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5.2.7. Viability assessment 
 
Viability of layered and freeze-dried bacteria was assessed immediately after drying (via 
layering or freeze drying) and after storage (at -20 or 4°C). 100 mg of the formulation was 
resuspended in 1 ml MRS broth and a dilution series was plated out. For L. jensenii and L. 
crispatus 128 a plate pour method was used with MRS agar as growth medium. For L. gasseri 
and L. crispatus 125 a plate spread method was used with TSA, enriched with 5 % sheep 
blood. After 48 h anaerobic incubation (BugBox, Ruskinn Technology, Pencoed, UK) at 37°C 
the colony forming units were counted. 
 
5.2.8. In vivo evaluation of the colonisation potential of a pellet and powder 
formulation containing Lactobacillus species 
 
Hard gelatin capsules were filled with 5 × 106 L. jensenii, L. crispatus 125 and L. crispatus 
128 formulated as a pellet or powder formulation. The pellet formulation consisted of starch-
based pellets layered with bacteria using 10 % lactose/20 % skim milk as stabilising matrix. 
The powder formulation consisted of bacteria stabilised in 10 % lactose/20 % skim milk. A 
double-blind, randomised, parallel study was performed with 16 healthy volunteers. 8 women 
followed a 5-day treatment with pellet-filled capsules, 8 women followed a 5-day treatment 
with powder-filled capsules. The same restrictions were applied as in the in vivo study with 
the placebo formulations (see Chapter 4). 
On day 1, 2, 3, 4 and 5 one capsule was administered by the volunteers just before bedtime 
using a vaginal applicator. On day 22 the intake of the monophasic pill was stopped.  
On day 6, 9, 12 and 33 (eleven days after pill stop) the volunteer underwent a gynaecological 
examination. The vagina and rectum were swabbed with an Eswab (Copan diagnostics, 
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Corona, CA, USA). Swabs were used for Gram-staining and culturing (to identify H2O2-
producing strains) (using the method described in Chapter 4) at the Laboratory for 
Bacteriological Research (Ghent University Hospital). 
  
5.3. Results and discussion 
 
5.3.1. Viability after layering and freeze-drying 
 
The survival data of the formulations after layering and freeze-drying are summarised in 
Table 2 and 3, respectively. The viability immediately after drying was expressed as 
percentage survival i.e. the ratio of viable bacteria after drying to the number of bacteria in the 
suspension used for drying. The viabilities after storage are expressed as relative viabilities 
(%) i.e. the ratio of viable bacteria after storage to the number of bacteria immediately after 
drying. 10 % lactose/20 % skim milk was selected as stabilising matrix as this combination 
showed the best stabilising capacities for a L. lactis strain (Poelvoorde et al. 2008). 
For all strains freeze-drying resulted in higher survival ratios immediately after drying 
compared to layering. L. gasseri could not be processed via layering as the pellets 
agglomerated during processing due to the sticky nature of the L. gasseri-containing matrix. 
However the layered formulation of L. jensenii and L. crispatus 128 offered the best stability 
during storage. These results confirmed that survival after drying was strain dependent 
(Andersen et al. 1999; Carvalho et al. 2004b; Champagne et al. 1991; To and Etzel 1997) and 
that long term storage - even at low temperature- resulted in a large decrease of viability. 
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Table 2 Viability (%) of the Lactobacillus strains after layering on inert microcrystalline cellulose carries and 
storage at 4°C 
 L. jensenii L. crispatus 125 L. crispatus 128 L. gasseri 
After layeringa 5.57 1.73 10.91 - 
1 month storage at 
4°Cb 14.55 28.06 50.96 - 
9 months storage at 
4°Cb 0.34 1.78 16.93 - 
a the percentage survival immediately after drying is expressed as the ratio of viable bacteria after drying to the 
number of bacteria in the suspension used for drying, b the percentage survival after storage is expressed as the 
ratio of viable bacteria after storage to the number of bacteria immediately after drying 
 
Table 3 Viability (%) of the Lactobacillus strains after freeze-drying and storage at 4°C 
 L. jensenii L. crispatus 125 L. crispatus 128 L. gasseri 
After freeze-dryinga 27.44 6.02 13.14 35.34 
1 month storage at 
4°Cb 0.12 55.13 2.37 5.93 
9 months storage at 
4°Cb 0.03 18.39 0.02 0.07 
a the percentage survival immediately after drying is expressed as the ratio of viable bacteria after drying to the 
number of bacteria in the suspension used for drying, b the percentage survival after storage is expressed as the 
ratio of viable bacteria after storage to the number of bacteria immediately after drying 
 
For vaginal delivery pellets and powder were packed in size 00 capsules and vaginally 
administered using a commercially available applicator (as described in Chapter 4). About 
750 mg pellets or 400 mg freeze-dried powder can be packed in one capsule and the number 
of bacteria per capsule immediately after drying and after 9 months storage is presented in 
Table 4. Although immediately after drying a high dose of bacteria per capsule was obtained, 
the dose decreased to about 106 cfu per capsule after 9 months storage at 4°C. Although a 
dose finding study of Reid et al. (2001) for vaginal colonisation via the oral route concluded 
that an oral dose of 108 cfu was sufficient to obtain vaginal colonisation, the required dose for 
vaginal administration is unknown. However, based on the local delivery via capsules and the 
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direct colonisation of the lactobacilli one can expect that a lower dose is required for the 
vaginal route compared to oral administration of lactobacilli. 
Similar stability data were obtained by Maggi et al. (2000): a 3 log decrease of viability for an 
freeze-dried L. crispatus strain and a 2 log reduction for a freeze-dried L. gasseri strain after 1 
year storage at 4°C using a combination of skim milk and malt extract as stabilising matrix. 
Otero et al. (2007) combined skim milk, lactose and sucrose with the highest survival ratio for 
a 6 % skim milk/6 % lactose-mixture: 9.00 log cfu/g for L. gasseri CRL1412 and 8.84 log 
cfu/g for L. gasseri CRL 1421 after 9 months storage at 2-8°C when the freeze-dried powder 
was packed in sealed ampoules. In contrast, packing of the freeze-dried powder in gelatin 
capsules reduced the viability after 9 months to 8.62 and 7.88 log cfu/g for L. gasseri CRL 
1412 and 1421, respectively. 
 
Table 4 Viability of the Lactobacillus strains after drying via layering and freeze-drying and after 9 months 
storage at 4°C. The viability is expressed as the number of colony forming units (cfu) per size 00 capsule. 
 L. jensenii L. crispatus 125 L. crispatus 128 L. gasseri 
After layering 7.85 × 108 9.12 × 107 3.42 × 108 - 
9 months storage at 
4°C 2.69 × 10
6 1.63 × 106 5.15 × 107 - 
After freeze-drying 2.27 × 1010 1.86 × 109 2.42 × 109 5.96 × 109 
9 months storage at 
4°C 6.25 × 10
6 3.42 × 108 3.68 × 105 4.29 × 106 
 
Although hard gelatin capsules would be preferred over HPMC capsules for vaginal delivery 
of the probiotics based on their slightly faster vaginal disintegration compared to HPMC 
capsules (Chapter 4), the higher water content of the hard gelatin capsule shells (13-15% vs. 
2-3% for HMPMC capsules) could have a detrimental effect on storage stability of the 
microorganisms. Therefore pellets layered with L. jensenii and a freeze-dried formulation of 
L. jensenii were packed into hard gelatin as well as HPMC capsules (which are both 
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commonly used in the pharmaceutical industry) and the viability was monitored over a 9 
month period during storage at 4°C (Table 5). Although the 9 months viability had decreased 
in all cases (independent of formulation and packaging), there was no difference in viability 
of L. jensenii stored in HPMC or gelatin capsules. Hence the higher water content of the 
gelatin capsules did not affect bacterial survival during storage. 
 
Table 5 Viability of L. jensenii after drying via layering and freeze-drying and after 9 months storage at 4°C 
(relative humidity of 20%) in gelatin or HPMC capsule. The viability is expressed as the number of colony 
forming units (cfu) per size 00 capsule. 
 Gelatin capsules HPMC capsules 
After layering 3.41 × 108 3.41 × 108 
9 months storage at 
4°C 2.92 × 10
6 1.39 × 106 
After freeze-drying 8.70 × 108 8.70 × 108 
9 months storage at 
4°C 3.77 × 10
6 4.72 × 106 
 
Despite the high load after processing a higher cell load is preferred to assure colonisation and 
long term storage stability (>9 months). To improve bacterial survival after drying and storage 
different approaches were used: (1) increasing the cell load of the drying suspension and (2) 
modification of the layering matrix. Via optimisation of the growth conditions of the different 
strains it was attempted to achieve a higher cell load of the drying suspension. The 
atmospheric conditions (aerobic, anaerobic, under CO2), the growth conditions (with or 
without shaking) and the growth medium (phosphate, acetate and carbonate buffered growth 
media) were included as variables. However, independent of the conditions the cell 
concentration in the medium could not be improved. As increasing the bacterial cell 
concentration in the stationary phase culture was not possible by changing the incubation 
conditions, a 50 L fermentation of L. crispatus 128 was performed to obtain a higher 
concentration factor after resuspending the cell pellet (500-fold vs. 100-fold). However, after 
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this large scale fermentation a cell pellet of 507 g was obtained, which could not be 
resuspended in 100 ml of stabilising matrix used for the layering experiment.  
In a second approach the stabilising matrix was modified to achieve a higher survival rate. 
Ascorbic acid was added to the stabilising matrix as vitamin C has an anti-oxidant function 
which can be beneficial during storage of dried bacteria by delaying auto-oxidation of 
membrane phospholipids (Carvalho et al. 2004b). L. jensenii was selected as test strain. 
Viability after storage improved as 1 % vitamin C was added to a 10 % lactose/20 % skim 
milk matrix for layering of the L. jensenii strain (using a 1 L overnight culture which was 10-
fold concentrated in the stabilising matrix): viability immediately after layering was 13.01 % 
and the survival rate after 12 months storage at 4°C improved from 5.40 % without vitamin C 
to 68.14% in combination with vitamin C (Fig. 2). Zarate and Nader-Macias (2006) also 
reported stability improvement after freeze-drying of different Lactobacillus strains if vitamin 
C was added to lactose/skim milk matrices. 
Lactose was substituted by trehalose as stabilising disaccharide as special stabilising 
capacities are attributed to trehalose based on its higher Tg compared to other dissaccharides, 
which is maintained if small amounts of water were added (Crowe et al. 1996). However, 
incorporation of trehalose in the formulation did not improve stability (Fig. 2). 
In another experiment trehalose was added to the growth medium of the L. jensenii strain as a 
growth medium containing other sugar substrates produces cells with distinct morphological 
and physiological characteristics, which can be reflected in their resistance to stress 
conditions (Carvalho et al. 2004a; Carvalho et al. 2004b). A 10 % lactose/20 % skim milk 
mixture was used as external stabilising matrix. However, after addition of trehalose to the 
growth medium similar survival rates were obtained after drying or storage (Fig. 2). Moreover 
the carriers tended to agglomerate during layering, possibly due to the production of 
exopolysaccharide (EPS) by the bacteria as this depends on the carbon source present in the 
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growth medium (Degeest et al. 2001). However, no correlation was found between EPS 
production and survival after freeze-drying or during storage of freeze-dried bacteria 
(Carvalho et al. 2004a; Looijesteijn et al. 2001). 
 
4
5
6
7
8
0 1 2 3 4 5 6 7 8 9 10 11 12
Months
vi
ab
ili
ty
 lo
g 
(c
fu
/1
00
 m
g)
10% lactose/20% skim milk 10% lactose/20% skim milk/1% vit C
10% lactose/20% skim milk trehalose in grow th medium 10% trehalose/20% skim milk
 
Figure 2 Viability (cfu/100mg) of L. jensenii after layering and storage using different stabilising matrices 
 
5.3.2. Tangential flow filtration 
 
Centrifugation is generally used to harvest bacteria from a liquid culture. However, 
centrifugation is a time consuming process and it can damage the bacteria due to the large 
forces generated during centrifugation. In addition up-scaling of the centrifugation process is 
troublesome. As alternative harvesting technique tangential flow filtration was evaluated 
(Naja et al. 2006; Sundaran et al. 2002). Tangential flow filtration is a pressure-driven 
membrane separation process, which provides a separation based on the molecular size of the 
constituents. Soluble and low molecular weight materials pass through the membrane and 
bacteria which are larger than the membrane pore size are retained. The feed is pumped across 
the membrane surfaces and the pressure gradient through the membrane acts as a driving 
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force to push the solutes and the water through the membrane. Up-scaling is easier and 
tangential flow filtration can be seen as a continuous process, because feed can be 
continuously added during the process as permeate is removed. A drawback of tangential flow 
filtration is that not all the growth medium is removed during filtration, which is not 
acceptable for our application as residues of the MRS-growth medium induce sticking 
problems during layering. As a consequence an additional centrifugation step was required to 
maximize removal of the growth medium before resuspending the cell pellet in a solution of 
stabilising sugar. 
Bacterial suspensions containing the different Lactobacillus species were processed via 
centrifugation and tangential flow filtration to assess the cell load obtained via both processes 
as well as the effect of this pre-processing step on the survival rate after freeze-drying. The 
concentration of bacteria in the stabilising matrix after centrifugation and microfiltration and 
the viability after freeze-drying is shown in Figure 3 and 4, respectively. For all bacteria the 
concentration in the stabilising matrix was comparable after centrifugation and tangential 
flow filtration. Since a large fraction of bacteria (between 16.9 and 35.3 %) adhered to the 
membrane, an additional flushing step was required to obtain a high yield of the tangential 
filtration process.  
If these stabilising matrices were freeze-dried, similar viability data were obtained for both 
concentrating procedures, indicating that there was no influence of the harvesting technique 
on the ability to withstand freeze-drying. Since centrifugation did not damage the bacteria 
tangential flow filtration did not offer an added value.  
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Figure 3 Viability log (cfu/ml) in the stabilising matrix after centrifugation and tangential flow filtration  
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Figure 4 Viability log (cfu/100 mg) in the freeze-dried powder after centrifugation and tangential flow filtration 
 
5.3.3. In vivo colonisation study 
 
During a clinical trial the colonisation potential of the probiotic strains L. jensenii, L. 
crispatus 125 and L. crispatus 128 was evaluated and the colonising capacity of the pellet and 
powder formulation (both containing 5 × 106 of each strain) was compared (Table 6). L. 
gasseri was excluded as no layered multi-particulate formulation could be obtained. 
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At the start of the 5-day treatment L. jensenii was detected in two volunteers, L. crispatus 128 
strain was present in 8 of 16 volunteers and L. crispatus 125 was not found at screening. In 
those subjects that were already colonised at screening by a strain with an RAPD pattern 
(random amplification of polymorphic DNA) that equals the patterns of the administered 
probiotic strains, the colonisation potential of that specific strain could not be determined. It 
was defined that colonisation was achieved if a specific strain was present from day 6 until 
day 33.  
On day 6 (1 day after the end of the treatment) L. jensenii was detected in 7 of the 14 
volunteers. All but one of these women were still colonised with this strain on day 12 and 33. 
In three other volunteers L. jensenii was only recovered on one or two check-up days, 
indicating only a transient colonisation.  
L. crispatus 128 colonised just one volunteer from day 6 until day 33. In two other volunteers 
a temporary colonisation was detected. These low colonisation results can be due to the 
administered dose (i.e. 5 × 106), which might be too low to allow colonisation with this strain. 
Similar results were seen for L. crispatus 125 since this strain was only found in one subject 
after treatment.  
The rectum was also swabbed to evaluate rectal colonisation with the probiotic strains as the 
rectum can serve as reservoir for vaginal colonisation. In 8 of the 16 subjects H2O2- producing 
strains were detected in the rectum at one follow-up day and in 4 of these women these strains 
were identified as the administered probiotic strains. However, rectal colonisation was of 
short duration as the strains were detected on a single day and not over a longer period.  
Of 12 women having a normal vaginal microflora at the onset of the study, one person 
evolved to bacterial vaginosis (III) at day 33, but one women having bacterial vaginosis at the 
start evolved to a less disturbed microflora (Ibc) after the study. However, these abnormal 
microflora did not influence the conclusion from the colonisation study. 
126
Development of a vaginal formulation of Lactobacillus species and in vivo  evaluation in healthy volunteers 
As vaginal colonisation was poor for the L. crispatus strains and rectum colonisation was only 
temporary, only the vaginal colonisation of L. jensenii was taken in consideration to 
distinguish between the pellet and powder formulation. From the 6 volunteers that were 
colonised with L. jensenii from day 6 until day 33, three received the pellet formulation and 3 
the powder formulation, indicating that the formulation itself did not influence colonisation.  
 
Table 6 Colonisation potential according to Gram-stain results  
 Screening Day 6 Day 9 Day 12 Day 33 
 Pellet formulation 
Volunteer 1 Ia Ia Ia Ia Iab 
Volunteer 2 Ia Ia Ia Ia Ia 
Volunteer 3 Ia Ib Ic Ic Ic 
Volunteer 4 Ia Ia Iab Ia Iab 
Volunteer 5 Ia Ia Iab Ib Ia 
Volunteer 6 Iab Ia Iabc II III 
Volunteer 7 Iab Ia Ia Ia Iab  
Volunteer 8 Ib Ia Iab Ib Iab 
 Powder formulation 
Volunteer 1 Ia Ia Ia Ia Iab 
Volunteer 2 Iab Iab Iabc Iab Ia 
Volunteer 3 Iac Iac Iabc Ibc Iabc  
Volunteer 4 Ib + yeast Ib + yeast Ib + yeast Ib + yeast Iab 
Volunteer 5 Ic + yeast Iabc + yeast III + yeast III + yeast III + yeast 
Volunteer 6 Ic Ic  Ic  Ic III  
Volunteer 7 III III III III Ibc 
Volunteer 8 IV Iac Iab Iab IV 
Red: abnormal microflora 
 Colonised with 
L. jensenii 
 Colonised with 
L. crispatus 128 
 Colonised with 
L. crispatus 125 
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5.4. Conclusion 
 
The survival rate of four Lactobacillus species after drying via freeze-drying or layering was 
strain dependent. For all strains under investigation freeze-drying resulted in a higher viability 
immediately after layering. However for 3 of the tested bacteria viability decreased 
significantly after 1 month storage of the freeze-dried powder, whereas the layered pellets had 
a slower decrease in viability. The highest stability during storage at 4°C was obtained if 
vitamin C was added as an anti-oxidant to the layered pellet formulation. 
Vaginal colonisation of the L. jensenii strain was detected after vaginal administration of 
layered pellets as well as a powder formulation, but the clinical effect of this colonisation 
must be confirmed in patients with recurring bacterial vaginosis. 
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GENERAL CONCLUSION AND FUTURE 
PERSPECTIVES 
 
This research work described the formulation of dry, viable bacterial strains, which can be 
used for their health promoting or therapeutic characteristics. Layering was identified as a 
suitable processing technique for the development of a dry multi-particulate formulation 
containing viable genetically modified Lactococcus lactis, which can be used for treatment of 
patients suffering from Crohn’s disease. Multi-particulates assure a fast gastric emptying and 
can be enteric coated in the same process step, which make them more advantageous than 
coated capsules filled wit freeze- or spray-dried powder. Layering of L. lactis on inert carriers 
using a combination of lactose and skim milk as stabilising matrix resulted in a high load of 
viable L. lactis. However, long term storage without loss of viability was only possible at -
20°C, despite the addition of different stabilising molecules to the layered formulation. 
Although the viability of L. lactis decreased during simulated gastric passage of Eudragit® 
FS30D coated pellets, a sufficient amount of viable IL-10 producing L. lactis could be 
delivered to the ileum, the intended target site. Release targeted to the ileum, the most 
infected part of the intestine in patients with Crohn’s disease, could be achieved using 
Eudragit® FS30D, if a small coating thickness was used or if the amount of free carboxylic 
groups on the polymer was increased by basic hydrolysis. 
 
The layered pellet formulation was also suitable for vaginal delivery of probiotic strains 
(Lactobacillus jensenii and Lactobacillus crispatus) using starch-based pellets as carrier. 
These starch-based pellets were well retained and distributed in the vaginal cavity in contrast 
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to non-disintegrating microcrystalline cellulose pellets and freeze-dried powder. Moreover, 
starch-based pellets did not influence the natural pH or microflora. Vaginal colonisation was 
obtained for L. jensenii after a 5-day treatment in healthy volunteers using a dose of 5 × 106 
cfu. However, future optimisation work is recommended as no colonisation was obtained for 
the L. crispatus strains and the clinical effect in patients with recurrent bacterial vaginosis 
must be demonstrated. Recently, a clinical trial was started in patients with bacterial 
vaginosis. Bacterial vaginosis patients will receive a vaginal probiotic formulation  containing 
L. jensenii and L. crispatus on 5 consecutive days immediately after a traditional 
metronidazole treatment. One month afterwards patients will receive a second cure with the 
same dose of probiotic bacteria. This treatment group will be compared with a control group 
who receives a placebo formulation after antibiotic treatment. The vaginal colonisation with 
the administered strains and the (re-)occurrence of bacterial vaginosis will be evaluated. 
 
The main issue in the formulation of this type of viable therapeutics, is their viability after 
drying and storage. As the long term storage stability of all strains evaluated in this research 
project was poor, additional research is required to optimize the formulation and/or processing 
technique to improve the long term survival of the microorganisms during storage since a 
reliable formulation with an acceptable shelf life is an essential aspect for the successful 
application of bacteria as therapeutics in disease treatment. Addition of vitamin C to the 
layered formulation of L. jensenii resulted in promising stability results, but this must be 
further explored for the other strains. The use of different growth media and growth 
conditions and the removal of fermentation products and other by-products of microbial 
metabolism before drying was not evaluated in the present studies. These (and other 
optimisations) may increase the survival of the bacteria during drying and storage. 
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In addition, in case of oral delivery, gastric protection was poor and should be improved to 
assure that a proper dose reaches the intestine. 
Although the potential of a multi-particulate starch-based pellet formulation for vaginal 
delivery of probiotics was clearly highlighted in this study, the opportunities of this novel 
vaginal delivery platform for administration of conventional drugs (e.g. microbiocides) needs 
to be further investigated to identify the full potential of this delivery system. For a proper 
evaluation of the vaginal behaviour of multi-particulates, a non-invasive evaluation technique 
should be used, like gamma scintigraphy, which does not interfere with the distribution and 
retention of the formulation. Moreover, the development of a suitable animal model to 
evaluate vaginal distribution and retention of pharmaceutical formulations will be of high 
value, as it is not possible to perform all tests directly on humans. As capsules showed a very 
slow vaginal disintegration (in some cases more than 6 h), it should be evaluated if another 
delivery device can be used. 
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SUMMARY 
 
 The aim of this research project was to develop multi-particulate dosage forms for 
delivery of lactic acid bacteria: (a) the development of an oral dosage form 
containing a high concentration of viable, genetically modified, IL-10 producing 
Lactococcus lactis (b) the development of a formulation for delivery of health-promoting 
strains of lactic acid bacteria (referred to as probiotics) to the vagina. In addition to the 
viability of the lactobacilli strains incorporated in the formulation the vaginal retention time 
and spreading of the formulation in the vaginal cavity are essential quality parameters of this 
vaginal formulation. Chapter 1 reviews the use of genetically modified Lactococcus lactis and 
probiotic Lactobacillus strains as therapeutics in the treatment of Crohn’s disease and 
bacterial vaginosis, respectively. The strategies used to stabilise lactic acid bacteria in solid 
dosage forms and the processing techniques used to manufacture the oral and vaginal dosage 
forms are also discussed in this introductory chapter.  
1 
 
 In Chapter 2 an oral multi-particulate formulation of viable Lactococcus lactis Thy 
12 was developed using fluidized bed layering on inert carriers. Bacteria were 
suspended in a stabilising matrix, sprayed and subsequently dried on pellets. A 
multi-particulate formulation was selected as dosage form as it assures fast gastric emptying 
of the small subunits of the formulation and after layering of the microorganisms on an inert 
carrier the formulation can be immediately enteric coated using the same process equipment. 
Chapter 2.3.1. describes the optimisation of the Bioscreen turbidity method, used for viability 
assessment of L. lactis in the dried samples. In chapter 2.3.2. the layering process was 
optimised by modification of different process and formulation parameters. Atomising 
2 
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pressure during spraying and the type of inert carrier (microcrystalline cellulose versus starch-
based pellets) did not influence bacterial viability. A 5 % lactose matrix provided the best 
stabilisation of L. lactis after a 30 min layering process (remaining viability: 8.9 %), however 
if the process time was prolonged the addition of 10 % skim milk was needed to achieve a 
high survival rate. When increasing the concentration of bacteria in the layering suspension, a 
higher amount of stabilising matrix was required to maintain the viability of the 
microorganisms. If the formulation was stored for 12 months at -20°C and a relative humidity 
of 20 % the viability did not decrease, whereas storage at 8°C already resulted in a significant 
decrease of viability after 1 month storage. Microencapsulation of L. lactis Thy 12 (Chapter 
2.3.3.) in a sodium alginate matrix yielded a similar viability compared to layering as 
processing technique, however the resulting particles were too sticky and not suitable for 
delivery of L. lactis. 
 
 As L. lactis Thy 12 is highly sensitive to the gastric environment, an enteric-coated 
formulation is required to deliver viable L. lactis to the intestine. Moreover, as 
Crohn’s disease mainly affects the ileal part of the intestine, release must be targeted 
to this site. When the multi-particulate formulation was enteric coated with Eudragit® FS30D 
the viability decreased in function of coating thickness (Chapter 3.3.1.). Moreover, enteric 
protection was limited as only 1.1 % of the bacteria survived after 2 h in 0.1 N HCl. As the 
enteric coat was toxic for the bacteria as evidenced by the viability data, HPMC or PVA-
based subcoats were applied to prevent direct contact between the bacteria and the enteric 
coat. Only Opadry® II did not significantly decrease the viability after subcoating, however 
after enteric coating of these subcoated pellets, the viability of the formulation was low.  
3 
To obtain ileum targeting (i.e. release at pH 6.8), two different approaches were used (Chapter 
3.3.2.): decreasing the coating thickness and modifying the structure of the enteric polymer. 
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Although a coating thickness corresponding to 15 % polymer weight gain (Eudragit® FS30D) 
only resulted in complete release of the content of the pellets at pH 7.4, ileum targeting could 
be improved by reducing the coating thickness: drug release from pellets coated to a weight 
gain of 5 % resulted in complete release after 100 min in pH 7.0 phosphate buffer. Chemical 
modification of the Eudragit® FS30D polymer structure to increase the concentration of free 
carboxylic groups also resulted in a polymer suitable for ileum targeting.  
 
 In Chapter 4 a vaginal formulation for the delivery of probiotic Lactobacillus 
strains was developed. The behaviour of a multi-particulate pellet formulation (as 
novel vaginal delivery system for probiotics) was compared with a freeze-dried 
lactose/skim milk powder. An optimal vaginal formulation should distribute uniformly over 
the vaginal mucosa and be retained for a sufficient time to allow complete drug release in the 
vaginal cavity. Non-disintegrating microcrystalline cellulose pellets clustered around the 
vaginal fornix and 24 h after administration only a small fraction of the pellets could be 
detected in the vagina. In contrast, 24 h after administration, starch-based pellets had evenly 
distributed over the vaginal mucosa. After administration of HPMC or gelatine capsules filled 
with pellets vaginal disintegration of these systems was slow (in some cases over 6 h), 
probably related to the low amount of fluid present in the vagina. A clinical trial in healthy 
volunteers showed that starch-based pellets and freeze-dried lactose/skim milk powder did not 
disturb the vaginal pH and microflora.  
4 
 
 Four different strains of Lactobacillus  species (i.e. L. jensenii, L. crispatus 125, L. 
crispatus 128 and L. gasseri) were layered on inert carriers or freeze-dried using 10 
% lactose/20 % skim milk as stabilising matrix. Immediately after drying, freeze-
drying resulted in a higher survival compared to layering. Layering of L. gasseri was not 
5 
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possible as the sticky nature of the pellets agglomerated the particles during processing. Long 
term storage of the L. jensenii and L. crispatus 128 strains was better for the layered pellets. 
After addition of vitamin C to the drying matrix, the L. jensenii layered formulation could be 
stored for 12 months at 4°C with only a limited drop in viability (0.5 log reduction). 
Centrifugation and tangential flow filtration were used to harvest the microorganisms from 
the growth medium and both resulted in similar process yields. 
Layered starch-based pellets and freeze-dried powder, both containing 5 × 106 of L. jensenii, 
L. crispatus 125, L. crispatus 128, were vaginally administered to determine the colonisation 
potential of these formulations in healthy volunteers. The formulations were packed in 
capsules, administered on 5 consecutive days and the colonisation potential of the formulation 
was evaluated on day 6, 9, 12 and 33. Colonisation was only achieved with L. jensenii: in 7 of 
16 volunteers this strain was detected in the vaginal microflora at all check-up days. As some 
of these volunteers (n=4) received the pellet and other the powder formulation (n=3) the 
formulation had no influence on vaginal colonisation. L. crispatus vaginally administered as a 
probiotic did not induce colonisation as a higher dose might be required to achieve this goal. 
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SAMENVATTING 
 
 Het doel van dit onderzoeksproject was de ontwikkeling van een multi-particulaire 
formulatie van melkzuurbacteriën: (a) de ontwikkeling van een orale formulatie met 
een hoge concentratie aan levende, genetisch gemodificeerde en IL-10 
producerende Lactococcus lactis (b) de ontwikkeling van een vaginale formulatie van 
gezondheidsverbeterende melkzuurbacteriën (probiotica). Naast de bepaling van de 
leefbaarheid van de Lactobacillus stammen in de formulatie werd ook de vaginale retentie en 
distributie van de formulatie nagegaan, aangezien dit een essentiële parameter is voor een 
goede vaginale geneesmiddelvorm. Hoofdstuk 1 bespreekt het gebruik van genetische 
gemodificeerde Lactococcus lactis en probiotische Lactobacillus stammen als therapeutica in 
de behandeling van de ziekte van Crohn en bacteriële vaginose, respectievelijk. De strategieën 
om melkzuurbacteriën te stabiliseren in droge vorm en de productietechnieken gebruikt om de 
orale en vaginale formulatie te produceren worden besproken in dit inleidende hoofdstuk. 
1 
 
In Hoofdstuk 2 werd een multi-particulaire formulatie van levende Lactococcus 
lactis kiemen ontwikkeld via wervelbed layering op inerte dragers. Bacteriën 
werden gesuspendeerd in een stabiliserende matrix en vervolgens gesproeid en 
gedroogd op pellets. Deze multi-particulaire formulatie heeft als voordeel dat ze snel geklaard 
wordt uit de maag en bovendien kan deze formulatie in hetzelfde toestel maagsapresistent 
omhuld worden. Hoofdstuk 2.3.1. beschrijft de optimalisatie van de Bioscreen 
turbiditeitsmethode, die gebruikt wordt om de leefbaarheid van de gedroogde L. lactis kiemen 
te bepalen. In Hoofdstuk 2.3.2. werd het layeringsproces geoptimaliseerd door verschillende 
proces- en formulatieparameters te wijzigen. De atomiserende druk tijdens het sproeien en het 
type inerte drager (microkristallijne cellulose of zetmeelpellets) had geen invloed op de 
2 
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leefbaarheid van de kiemen. Een 5 % lactose matrix resulteerde in de hoogste leefbaarheid 
van L. lactis na een layeringsproces van 30 min (leefbaarheid van 8,9 %), maar bij het 
verlengen van de procestijd tot 2 u was toevoeging van 10 % magere melk nodig om een hoge 
overleving te behouden. Wanneer de concentratie aan bacteriën in de layeringssuspensie 
verhoogd werd, was het tevens noodzakelijk om de hoeveelheid stabiliserende matrix te 
verhogen. Na bewaren van de formulatie voor 12 maand bij -20°C en een relatieve 
vochtigheid van 20 % was er geen daling in leefbaarheid, maar bewaring bij 8°C resulteerde 
reeds in een significante daling in leefbaarheid na 1 maand bewaring. De leefbaarheid na 
microencapsulatie van L. lactis (Hoofdstuk 2.3.3.) in een natriumalginaat matrix was 
vergelijkbaar met de leefbaarheid na layeren, maar de verkregen partikels waren te plakkerig 
en als dusdanig niet geschikt als bacteriële formulatie.  
3 
 
Aangezien de leefbaarheid van L. lactis aangetast wordt door de zure pH van de 
maag, moet de L. lactis formulatie omhuld worden met een maagsapresistent 
polymeer. Bovendien moet de vrijstelling van L. lactis getarget worden naar het 
ileum, aangezien deze zone van de dunne darm het meeste aangetast is bij de ziekte van 
Crohn. Omhullen van de gelayerde formulatie met Eudragit® FS30D, resulteerde in een daling 
in leefbaarheid bij toenemende omhullingdikte (Hoofdstuk 3.3.1.). Bovendien was de 
bescherming na 2 u 0.1 N HCl zwak, aangezien slechts 1,1 % van de kiemen overleefde. 
Aangezien de leefbaarheidresultaten wezen op een toxiciteit van het maagsapresistent 
polymeer, werd een HPMC of PVA subcoat aangebracht om het direct contact tussen de 
kiemen en de maagsapresistente coat te vermijden. Alleen Opadry® II resulteerde in geen 
significante daling na subcoaten, maar na omhullen met Eudragit® FS30D van deze 
gesubcoate pellets, werd slechts een lage leefbaarheid bekomen. 
142
Om ileum targeting (i.e. vrijstelling bij pH 6.8) te bereiken werden 2 verschillende 
benaderingsmethoden gebruikt (Hoofdstuk 3.3.2.): verminderen van de dikte van de coat en 
modificatie van de structuur van het maagsapresistent polymeer. Een coatingdikte verkregen 
na omhullen tot een gewichtstoename van 15 % (Eudragit® FS30D) resulteerde pas in een 
volledige vrijstelling bij pH 7.4, maar na vermindering van de coating dikte werd ileum 
targeting verbeterd: na 100 min bij pH 7 was de vrijstelling van pellets omhuld tot een 
gewichtstoename van 5 % compleet. Stijging van het aantal vrije carboxylgroepen door 
middel van chemische modificatie van het Eudragit® FS30D polymeer, resulteerde in een 
polymeer geschikt voor ileum targeting. 
 
In Hoofdstuk 4 werd een vaginale formulatie voor probiotische Lactobacillus 
stammen ontwikkeld. Het gedrag van een multi-particulaire pellet formulatie (als 
nieuw vaginaal toedieningsysteem voor probiotica) werd vergeleken met een 
gevriesdroogd lactose/magere melk poeder. Een optimale vaginale formulatie moet zich 
uniform spreiden over de vaginale mucosa en voldoende lang weerhouden worden om 
geneesmiddelvrijstelling te maximaliseren. Niet-desintegrerende microkristallijne cellulose 
pellets clusterden samen rond de vaginale fornix en 24 u na toediening werden slechts een 
kleine hoeveelheid pellets teruggevonden. In tegenstelling tot de niet-desintegrerende pellets, 
waren de zetmeelpellets uniform verspreid over de vaginale mucosa 24 u na toediening. 
Desintegratie van de gebruikte gelatine en HPMC capsules was traag (in sommige gevallen 
meer dan 6 u), vermoedelijk door de lage hoeveelheid vocht aanwezig in de vagina. In een 
klinische studie bij gezonde vrijwilligers werd aangetoond dat de zetmeelpellets en het 
gevriesdroogde lactose/ magere melk poeder de vaginale pH en microflora niet verstoren. 
4 
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4 verschillende Lactobacillus stammen (i.e. L. jensenii, L. crispatus 125, L. 
crispatus 128 en L. gasseri) werden gelayerd op inerte dragers of gevriesdroogd 
waarbij 10 % lactose/20 % magere melk gebruikt werd als stabiliserende matrix. 
Direct na drogen resulteerde vriesdrogen in een hogere overleving dan layeren. Layeren van 
L. gasseri was onmogelijk omwille van het kleven van de pellets tijdens het layeringsproces. 
Na bewaring voor 9 maand bij 4°C was de overleving van L. jensenii en L. crispatus 128 
beter voor de gelayerde pellets dan voor het gelyofiliseerde poeder. Na toevoeging van 
vitamine C aan de stabiliserende matrix kon de gelayerde formulatie van L. jensenii voor 12 
maand bewaard worden bij 4°C, waarbij slechts een kleine daling in leefbaarheid werd 
waargenomen (0,5 log reductie). Centrifugeren en tangentiële filtratie werden gebruikt om de 
kiemen te collecteren uit het groeimedium, waarbij beide technieken resulteerden in een 
vergelijkbare opbrengst. 
5 
Gelayerde zetmeelpellets en gevriesdroogd poeder, beide beladen met 5 × 106 L. jensenii, L. 
crispatus 125 en L. crispatus 128, werden vaginaal toegediend om het koloniserend vermogen 
van beide formulaties te bepalen bij gezonde vrijwilligers. De formulaties werden afgevuld in 
capsules en gedurende 5 opeenvolgende dagen toegediend, waarbij het koloniserend 
vermogen bepaald werd op dag 6, 9, 12 en 33. Enkel voor L. jensenii werd kolonisatie bereikt: 
in 7 van de 16 vrijwilligers werd op elke onderzoeksdag deze stam teruggevonden in de 
vaginale flora. Aangezien sommige van deze vrijwilligers (n = 4) de pellet formulatie 
gebruikten en sommige de poeder formulatie (n = 3), werd besloten dat de formulatie zelf 
geen invloed heeft op de vaginale kolonisatie. Een hogere dosis aan L. crispatus zal 
waarschijnlijk nodig zijn om kolonisatie met deze stam te bereiken.  
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